<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>PMC</source>
  <date>20140719</date>
  <key>pmc.key</key>
  <document>
    <id>PMC4520659</id>
    <passage>
      <infon key="name_2">surname:Bolis;given-names:Marco</infon>
      <infon key="name_3">surname:Garattini;given-names:Silvio Ken</infon>
      <infon key="name_0">surname:Centritto;given-names:Floriana</infon>
      <infon key="name_1">surname:Paroni;given-names:Gabriela</infon>
      <infon key="name_6">surname:Zanetti;given-names:Adriana</infon>
      <infon key="kwd">breast cancer luminal phenotype nuclear receptor RARalpha retinoic acid</infon>
      <infon key="name_4">surname:Kurosaki;given-names:Mami</infon>
      <infon key="name_5">surname:Barzago;given-names:Maria Monica</infon>
      <infon key="name_8">surname:Scott;given-names:Mark Francis</infon>
      <infon key="name_9">surname:Pattini;given-names:Linda</infon>
      <infon key="lpage">972</infon>
      <infon key="fpage">950</infon>
      <infon key="year">2015</infon>
      <infon key="name_7">surname:Fisher;given-names:James Neil</infon>
      <infon key="article-id_doi">10.15252/emmm.201404670</infon>
      <infon key="article-id_pmid">25888236</infon>
      <infon key="issue">7</infon>
      <infon key="volume">7</infon>
      <infon key="article-id_pmc">4520659</infon>
      <infon key="license">This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon>
      <infon key="type">front</infon>
      <infon key="name_18">surname:Garattini;given-names:Enrico</infon>
      <infon key="name_10">surname:Lupi;given-names:Monica</infon>
      <infon key="name_11">surname:Ubezio;given-names:Paolo</infon>
      <infon key="name_12">surname:Piccotti;given-names:Francesca</infon>
      <infon key="name_13">surname:Zambelli;given-names:Alberto</infon>
      <infon key="name_14">surname:Rizzo;given-names:Paola</infon>
      <infon key="name_15">surname:Gianni';given-names:Maurizio</infon>
      <infon key="name_16">surname:Fratelli;given-names:Maddalena</infon>
      <infon key="name_17">surname:Terao;given-names:Mineko</infon>
      <offset>0</offset>
      <text>Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RAR&#945; expression</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>135</offset>
      <text>Forty-two cell lines recapitulating mammary carcinoma heterogeneity were profiled for all-trans retinoic acid (ATRA) sensitivity. Luminal and ER+ (estrogen-receptor-positive) cell lines are generally sensitive to ATRA, while refractoriness/low sensitivity is associated with a Basal phenotype and HER2 positivity. Indeed, only 2 Basal cell lines (MDA-MB157 and HCC-1599) are highly sensitive to the retinoid. Sensitivity of HCC-1599 cells is confirmed in xenotransplanted mice. Short-term tissue-slice cultures of surgical samples validate the cell-line results and support the concept that a high proportion of Luminal/ER+ carcinomas are ATRA sensitive, while triple-negative (Basal) and HER2-positive tumors tend to be retinoid resistant. Pathway-oriented analysis of the constitutive gene-expression profiles in the cell lines identifies RAR&#945; as the member of the retinoid pathway directly associated with a Luminal phenotype, estrogen positivity and ATRA sensitivity. RAR&#945;3 is the major transcript in ATRA-sensitive cells and tumors. Studies in selected cell lines with agonists/antagonists confirm that RAR&#945; is the principal mediator of ATRA responsiveness. RAR&#945; over-expression&#160;sensitizes retinoid-resistant MDA-MB453 cells to ATRA anti-proliferative action. Conversely, silencing of RAR&#945; in retinoid-sensitive SKBR3 cells abrogates ATRA responsiveness. All this is paralleled by similar effects on ATRA-dependent inhibition of cell motility, indicating that RAR&#945; may mediate also ATRA anti-metastatic&#160;effects. We define gene sets of predictive potential which are associated with ATRA sensitivity in breast cancer cell lines and validate them in short-term tissue cultures of Luminal/ER+ and triple-negative tumors. In these last models, we determine the perturbations in the transcriptomic profiles afforded by ATRA. The study provides fundamental information for the development of retinoid-based therapeutic strategies aimed at the stratified treatment of breast cancer subtypes.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>2149</offset>
      <text>Introduction</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>2162</offset>
      <text>ATRA (all-trans retinoic acid) is used in the management of acute promyelocytic leukemia (Tallman et&#160;al, 1997; Lo-Coco et&#160;al, 2013), and the retinoid holds promise for the treatment of solid tumors like breast cancer (Garattini et&#160;al, 2014). The mechanisms underlying ATRA anti-tumor activity are unique, as the compound is endowed with anti-proliferative and cyto-differentiating activities, while it is only a weak cytotoxic agent (Garattini et&#160;al, 2007a,b). The retinoid pathway centers on ligand-dependent transcription factors belonging to the family of steroid nuclear receptors along with ERs/PRs (estrogen/progesterone receptors) and PPARs (peroxisome proliferator-activated receptors) (Chambon, 1996; Mark et&#160;al, 2009). Six retinoid receptors are known, that is RAR&#945;/&#946;/&#947; and RXR&#945;/&#946;/&#947;. Each RAR and RXR isoform is encoded by a distinct gene which is transcribed into splicing variants (Garattini et&#160;al, 2014). The active receptors consist of RXR-RAR heterodimers or RXR-RXR homodimers. While the RXR-RXR homodimers are the target of 9-cis retinoic acid and synthetic rexinoids, which are also promising agents in the chemoprevention of mammary tumors (Wu et&#160;al, 2002; Kong et&#160;al, 2005; Kim et&#160;al, 2006; Abba et&#160;al, 2008; Uray &amp; Brown, 2011), the RXR-RAR heterodimers are the classic mediators of ATRA activity. In the RXR-RAR complexes, RARs act as the ligand-binding moiety. ATRA is a pan-RAR agonist, binding RAR&#945;/&#946;/&#947; with the same affinity (Di Lorenzo et&#160;al, 1993; Gianni et&#160;al, 1996) and it also binds and activates PPAR&#946;/&#948; (Shaw et&#160;al, 2003; Berry &amp; Noy, 2007; Schug et&#160;al, 2007). In mammary tumors, ATRA-liganded RXR-RARs are purported to mediate growth inhibition, whereas RXR-PPAR&#946;/&#948; induces proliferation (Noy, 2010). ATRA is transported to the nucleus by CRABP1 and CRABP2 (cytosolic retinoic acid-binding proteins-1/-2) as well as FABP5 (fatty acid-binding protein-5) (Schug et&#160;al, 2007). While CRABP2 delivers ATRA to RXR-RARs, FABP5 targets RXR-PPAR&#946;/&#948; (Schug et&#160;al, 2007).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>4211</offset>
      <text>Breast cancer is a heterogeneous disease classified into subtypes according to the gene-expression profiles (Sorlie et&#160;al, 2003; Guedj et&#160;al, 2012). A rational use of ATRA and retinoids in breast cancer requires the definition of the sensitive subtypes (Garattini et&#160;al, 2014). Identification of the molecular determinants underlying retinoid sensitivity is another priority. The availability of representative cell lines characterized for the gene-expression profiles is a unique opportunity to establish the cellular/molecular determinants of retinoid sensitivity in mammary tumors. In this study, we tested the susceptibility of a large panel of breast cancer cell lines to ATRA, subsequently validating and extending the results in short-term tissue cultures of primary tumors. We identify RAR&#945; as the main retinoid receptor variant mediating the anti-tumor activity of the retinoid. In addition, we define gene sets, which are associated with ATRA sensitivity, and are of predictive potential. Finally, we determine the perturbations of the transcriptome afforded by ATRA in LuminalA/B and triple-negative (TN) tumors.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>5339</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>5347</offset>
      <text>Sensitivity of breast cancer cell lines to retinoids</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>5400</offset>
      <text>To define ATRA sensitivity, we selected 42 cell lines representative of breast cancer heterogeneity (Supplementary Table S1) and characterized for ER, PR, and HER2 status as well as the Luminal or Basal phenotype according to PAM50 (Tibshirani et&#160;al, 2002; Parker et&#160;al, 2009) (Supplementary Fig S1). The concentration-dependent growth-inhibitory effects of ATRA (0.001&#8211;10&#160;&#956;M) at 3, 6, and 9&#160;days were evaluated, as exemplified by the SKBR3, HCC-1954, and MDA-MB436 cell lines showing different ATRA sensitivity (Fig1A). The doubling time of each cell line and a number of other parameters associated with ATRA-dependent growth inhibition were determined (Supplementary Table S2). All these parameters are the basis for the calculation of the ATRA score, a new and robust index defining cell sensitivity to the growth-inhibitory action of ATRA (Supplementary Methods). The higher the ATRA score is, the higher is ATRA sensitivity. Development of this new index was necessary, since determination of standard IC50 values for the definition of sensitivity to the anti-proliferative effect of ATRA was deemed inadequate for at least two reasons. The IC50 is routinely and successfully used to assess cell sensitivity to cytotoxic compounds, while ATRA is predominantly a growth inhibitory and cyto-differentiating agent and it is largely devoid of a direct cytotoxic action (Garattini et&#160;al, 2007b, 2014). Given the slow kinetics of the response to the retinoid, we calculated the ATRA score between days 3 and 6.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>6919</offset>
      <text>Profiling of the breast cancer cell-line panel according to ATRA sensitivity</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>6996</offset>
      <text> The graphs show the growth-inhibitory effect exerted by the indicated concentrations of ATRA in SKBR3, HCC-1954, and MDA-MB436 cells which are representative of lines characterized by a high, intermediate and low ATRA score, respectively. Each point is the mean&#160;&#177;&#160;SD of three replicate cultures. **Significantly lower than the corresponding vehicle-treated group (P-value&#160;&lt;&#160;0.01, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7402</offset>
      <text> Cell lines are ranked in ascending order according to the ATRA score. The plot distinguishes four separate groups of cell lines (D&#8211;A) with increasing ATRA scores, as indicated by the colored scale on the right. The cell lines are also grouped in tertiles, T1&#8211;T3, according to an ascending ATRA score. Each calculated value is representative of at least two independent experiments. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>7790</offset>
      <text>A panel of 42 breast cancer cell lines was challenged with increasing concentrations of ATRA (11&#160;nM&#8211;10&#160;&#956;M) for 3, 6, and 9&#160;days, and cell growth was determined.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>7957</offset>
      <text>The ATRA score provides a continuous series of values across our panel of cell lines and identifies four separable groups (A&#8211;D, Fig1B). The subsets with high and intermediate sensitivity (groups A and B) are enriched for cells with Luminal and ER+ phenotypes. Indeed, 14/16 of the cell lines in combined groups A and B are Luminal and 11/16 are ER+. Interestingly, SKBR3 and AU565, representing a subgroup of HER2+ tumors which is predicted to be sensitive to ATRA due to co-amplification of the RARA and ERBB2 loci (Paroni et&#160;al, 2012), are the only ER&#8722;/HER2+ cell lines present in group A. Similarly, HCC-1599 and MDA-MB157 are the only Basal cell lines in groups A and B, respectively. Group C clusters the cell lines characterized by low sensitivity to ATRA. In this group, the proportion of Luminal (6/14) and ER+ (3/14) cell lines is reduced. Group D concentrates ATRA-resistant lines, the majority of which is Basal (10/12). Thus, the ATRA scores indicate that a Luminal phenotype and ER expression are major determinants of cell sensitivity to the anti-proliferative action of ATRA. In contrast, a Basal phenotype represents a negative factor. Indeed, the proportion of Basal cell lines increases as the ATRA score decreases if our panel is divided in tertiles (T1&#160;=&#160;2/14; T2&#160;=&#160;6/14; T3&#160;=&#160;12/14) (Fig1B).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>9281</offset>
      <text>Being one of the two Basal lines with a high ATRA score and one of the rare breast cancer lines transplantable in mice (Zhang et&#160;al, 2013), HCC-1599 represents a unique model to validate our ATRA-sensitivity data in&#160;vivo. Thus, SCID mice bearing subcutaneous HCC-1599 xenografts were treated with ATRA (15 and 7.5&#160;mg/kg) or vehicle on a daily basis for 3&#160;weeks, and tumor growth was followed. A time- and dose-dependent reduction in the tumor volume is evident in mice treated with ATRA (Fig2A). With the highest dose of ATRA, the effect is already significant after 17&#160;days and is maintained for at least 10&#160;days after treatment discontinuation. The total body weight of mice is not different in the experimental groups, demonstrating lack of ATRA-dependent toxicity (Supplementary Fig S2). The results were validated by MRI analyses performed at 24&#160;days (Fig2B). Taken together, the results support the in&#160;vivo relevance of the cell-line studies.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10238</offset>
      <text>ATRA-dependent anti-tumor activity in HCC-1599-derived xenografts in&#160;vivo</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10313</offset>
      <text> The size of the tumors was determined with a caliper and the volume plotted. Each point is the mean&#160;&#177;&#160;SE of 20 tumors. *Significantly lower than the corresponding vehicle-treated group (P-value&#160;&lt;&#160;0.05, Student's t-test). **Significantly lower than the corresponding vehicle-treated group (P-value&#160;&lt;&#160;0.01, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>10646</offset>
      <text> Magnetic resonance imaging (MRI) analysis was performed on five animals/experimental group on day 24. The picture shows representative 2D images of tumor sections from one animal treated with vehicle and one animal treated with 15.0&#160;mg/kg ATRA. The bar graph shows the volume of the tumors calculated after 3D reconstruction of the MRI images. Each point is the mean&#160;&#177;&#160;SE of five tumors. The P-value of the comparisons of ATRA versus vehicle is shown. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>11104</offset>
      <text>SCID mice were xenografted subcutaneously with 10&#160;&#215;&#160;106 HCC-1599 cells on both sides. One week after transplantation 10 animals/experimental group were treated intraperitoneally with vehicle (DMSO) or two doses of ATRA (7.5 and 15.0&#160;mg/kg) once/day, 5&#160;days a week for a total of 24&#160;days. At the end of this period, treatment was discontinued until sacrifice.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>11469</offset>
      <text>Short-term cultures of mammary tumors: anti-proliferative responses to ATRA</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>11545</offset>
      <text>To confirm the results obtained with the cell lines, we used short-term cultures of mammary tumors (van der Kuip et&#160;al, 2006) derived from diagnostic Tru-cut procedures of 45 patients (Supplementary Table S3). To assess the anti-proliferative activity of ATRA, tissue slices were challenged with vehicle or the retinoid for 48&#160;h, the maximal time interval maintaining tumor cell viability in basal culture conditions. The growth of tumor cells was evaluated with Ki67 (Fig3A and B), which is an established biomarker of cell division and it is routinely used in the clinics to assess the proliferation rate of breast cancer. Ki67 is rapidly down-regulated by a number of anti-proliferative agents in short-term tissue cultures of primary tumors (Alagesan et&#160;al, 2015). Rapid down-regulation of the biomarker is of the outmost importance, given the relatively short exposure times to ATRA that our tissue culture model allows and the slow anti-proliferative effect exerted by the retinoid.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12537</offset>
      <text>ATRA-dependent anti-tumor activity in short-term cultures of primary breast tumors</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12620</offset>
      <text> The panel illustrates examples of the immuno-histochemical data obtained in four representative cases: (i) Luminal-A (Lum A); (ii) Luminal-B (Lum B); (iii) Her2+ with RARA coamplification (Her2+/RARA+) and (iv) triple negative (TN). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>12855</offset>
      <text> The percentage of Ki67-positive tumor cells in the 45 samples considered are illustrated by the bar graphs. Each value represents the mean&#160;&#177;&#160;SE of at least five separate fields for each experimental sample. *Significantly lower than the corresponding vehicle-treated control (P-value&#160;&lt;&#160;0.05, Student's t-test). **Significantly lower than the corresponding vehicle-treated control (P-value&#160;&lt;&#160;0.01, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>13280</offset>
      <text>Tissue slices deriving from surgical specimens were challenged with vehicle (DMSO) or ATRA (0.1&#160;&#956;M) for 48&#160;h.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>13393</offset>
      <text>The cases used in our study are classified according to standard clinical criteria and consist of 17 Luminal-A, 14 Luminal-B, 7 HER2+, and 7 TN (triple-negative) tumors. All the Luminal-A and Luminal-B tumors are characterized by &gt;&#160;70% ER+ cells. ATRA reduces the proliferation of 11 Luminal-A and 10 Luminal-B tumors (Fig3B). Except for growth inhibition of the two cases characterized by co-amplification of the ERBB2 and RARA loci (patients 26 and 67) (Paroni et&#160;al, 2012), the retinoid exerts no significant effect on HER2+ tumors. Only one of the TN or Basal cancers responds to ATRA. The data are consistent with the cell-line results and confirm that ATRA sensitivity is frequent in Luminal and ER+ tumors.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>14109</offset>
      <text>Associations between the cellular phenotype and genes of the retinoid pathway</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>14187</offset>
      <text>Known members of the retinoid pathway are likely to be major mediators of ATRA anti-tumor activity. Given the respective associations with ATRA sensitivity and refractoriness observed in cell lines and primary tumors, we evaluated whether the Luminal and Basal phenotype as well as ER and HER2 positivity influence the expression of retinoid receptors/binding proteins. Both the microarray and the RNA-seq data associated with our panel of cell lines indicate that the average levels of RAR&#945;, RXR&#945;, and CRABP2 are significantly higher in Luminal than Basal cells (Fig4), while FABP5 shows an opposite pattern. Thus, Luminal cells are predisposed to activate CRABP2/RAR&#945; upon ATRA challenge. In the context of Luminal cell lines, these mRNAs show the same expression profile in ER+ relative to ER&#8722; cells. In the HER2+ cellular context (SKBR3, AU565, and UACC812 cell lines), the data confirm that RARA co-amplification results in high levels of RAR&#945; (Paroni et&#160;al, 2012).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>15174</offset>
      <text>Associations between components of the retinoid signaling pathway and the phenotype in breast cancer cell lines</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>15286</offset>
      <text>The figure illustrates the associations between the indicated retinoid receptors/binding proteins and the Luminal versus Basal phenotype (left panels), ER positivity versus ER&#160;negativity (middle panels) as well as HER2 positivity versus HER2 negativity (right panels). The gene-expression microarray and RNA-seq data refer to 42 and 40 breast&#160;cancer cell lines, respectively. The P-values of the indicated comparisons after Student's t-test are shown in red. L (red)&#160;=&#160;Luminal cell lines; B (blue)&#160;=&#160;Basal cell lines; ER+ (red)&#160;= ER-positive cell lines; ER&#8722; (red)&#160;=&#160;ER-negative cell lines; ER&#8722; (blue)&#160;=&#160;ER-negative Luminal cell lines; H+ (red)&#160;=&#160;HER2-positive cell lines; H&#8722; (red)&#160;=&#160;HER2-negative cell lines; H+ (blue)&#160;=&#160;HER2-positive Luminal cell lines; H&#8722; (blue)&#160;=&#160;HER2-negative Luminal cell lines. fpkm&#160;=&#160;fragments per kilobase of exon per million fragments mapped.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>16184</offset>
      <text>To evaluate whether the expression patterns of retinoid receptors/binding proteins in cell lines recapitulate the situation in mammary tumors, we analyzed the TCGA RNA-seq dataset consisting of over&#160;1,000 breast tumors classified into Luminal-A, Luminal-B, HER2-like, Normal-like and Basal according to PAM50. Consistent with the cell-line data, Basal tumors synthesize the smallest amounts of RAR&#945;, RXR&#945;, and RXR&#947; and the highest levels of FABP5 (Fig5A and B). The analysis unmasks associations which are not evident in cell lines, that is, direct correlations between RAR&#946;/RXR&#946;/CRABP1/PPAR&#946;/&#948; expression and the Basal phenotype. Given the poor responsiveness of Basal cell lines to the retinoid (Fig1B), these results support the notion that FABP5 and PPAR&#946;/&#948; are negative determinants of ATRA sensitivity (Balmer &amp; Blomhoff, 2002; Kannan-Thulasiraman et&#160;al, 2010). As for RAR&#946;, its expression does not seem to be important for ATRA anti-tumor activity in breast cancer (Connolly et&#160;al, 2013). In conclusion, our data demonstrate that RAR&#945; is the only receptor with a high level of expression in the cellular phenotypes predicted to be responsive to ATRA.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17381</offset>
      <text>Associations between components of the retinoid pathway and breast cancer phenotype</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>17465</offset>
      <text>Associations between the expression of the indicated members of the retinoid pathway in the TCGA gene-expression database are shown. Mammary tumors are classified into&#160;Luminal-A, Luminal-B, HER2-like, Normal-like, and Basal according to the PAM50 fingerprint. The average expression levels and the corresponding SD values of the indicated members of the retinoid pathway are shown by the upper box plots. For each member of the retinoid pathway, significant differences between the indicated groups of tumors are shown in the lower table. Significant P-values for the indicated comparisons (Student's t-test) are shown in red.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>18093</offset>
      <text>Direct associations between RAR&#945; and ATRA sensitivity</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>18151</offset>
      <text>After grouping all the cell lines in ascending tertiles (T3 to T1) according to the ATRA score, we looked for associations between retinoid receptors/binding proteins and ATRA sensitivity. According to both the microarray and RNA-seq results, the average amounts of RAR&#945; are significantly higher in T1 (ATRA sensitive) than T3 (ATRA resistant) cell lines (Fig6A). No difference in the amounts of PPAR&#946;/&#948; (Fig6A), RAR&#946;, RAR&#947;, RXR&#945;, RXR&#946;, RXR&#947;, CRABP2, and FABP5 (Supplementary Fig S3) is evident. RAR&#945; is also significantly over-expressed in the T1 group, if the analysis of the microarray data is limited to the 22 Luminal cell lines and the trend is confirmed by RNA-seq, although the results do not reach statistical significance. In the microarray data, T1 cells express larger amounts of PPAR&#946;/&#948; (Fig6A) than the T3 counterparts, after restriction to the Basal subset (20 cell lines). Thus, RAR&#945; is likely to be a determinant of ATRA sensitivity in both the total and Luminal fraction of cell lines, while PPAR&#946;/&#948; may represent a positive factor in Basal cell lines.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>19273</offset>
      <text> The gene-expression microarray and RNA-seq data associated with 40 of the breast cancer cell lines were used for the analyses. The panels illustrate the associations of RAR&#945; and PPAR&#946;/&#948; with ATRA sensitivity. The left panels show the basal average levels of the indicated transcript in the cell lines belonging to the T1 and T3 groups (13 cell lines in each of the T1 and T3 groups) defined by ascending ATRA scores. The intermediate and right panels indicate the same results after stratification for the Luminal (microarray and RNA-seq data&#160;=&#160;7 cell lines in each of the T1 and T3 groups) and the Basal (microarray and RNA-seq data&#160;=&#160;7 cell lines in each of the T1 and T3 groups) phenotype, respectively. fpkm&#160;=&#160;fragments per kilobase of exon per million fragments mapped. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>20061</offset>
      <text> The basal expression levels of the indicated RAR-isoform variants were determined with the use of specific Taqman assays. The results are associated with ATRA sensitivity before (TOTAL) and after stratification of the cell lines for the Luminal and Basal phenotype as in (A). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>20339</offset>
      <text>Associations between components of the retinoid signaling pathway and ATRA sensitivity </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>20427</offset>
      <text>Data information: Significant P-values (Student's t-test) are indicated in red.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>20507</offset>
      <text>The complement of RAR splicing variants in cell lines and primary tumors: RAR&#945;3 as the major determinant of ATRA sensitivity</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>20636</offset>
      <text>RAR&#945; (RAR&#945;1-4), RAR&#946; (RAR&#946;1-2-5), and RAR&#947; (RAR&#947;1-5) splicing variants are known (Supplementary Fig S4). Quantitative PCR was used to determine basal expression of these variants in our panel of cell lines. In the majority (40/42) of the cell lines (Supplementary Fig S5A), RAR&#945;3 is the most highly expressed RAR&#945; mRNA, being at least one order of magnitude more abundant than RAR&#945;2 and RAR&#945;1. Extremely low levels of RAR&#945;4 are generally observed. Only RAR&#945;3 and RAR&#945;4 show significant co-regulation across the panel (Supplementary Fig S5B), consistent with transcriptional control by the same promoter. Luminal cells contain significantly larger amounts of RAR&#945;3, RAR&#945;1, and RAR&#945;4 mRNAs than the Basal counterparts (Table1). Higher levels of the same transcripts are also associated with ER positivity, although statistical significance is not reached if analysis is restricted to the Luminal cell lines. If associations between RAR&#945; variants and ATRA sensitivity are searched for, significant over-expression of RAR&#945;3 in T1 relative to T3 cell lines is evident (Fig6B). A similar, though less significant, association is observed with RAR&#945;1 and RAR&#945;4. After stratification for the Luminal/Basal phenotype, the association between RAR&#945;3 and ATRA sensitivity is maintained solely in Luminal cells.</text>
    </passage>
    <passage>
      <infon key="type">table_caption</infon>
      <offset>22016</offset>
      <text>Associations between the RAR&#945; splicing variants and the phenotype in breast cancer cells</text>
    </passage>
    <passage>
      <infon key="type">table</infon>
      <offset>22109</offset>
      <text>    RAR&#945;1 (mean&#160;&#177;&#160;SE) RAR&#945;2 (mean&#160;&#177;&#160;SE) RAR&#945;3 (mean&#160;&#177;&#160;SE) RAR&#945;4 (mean&#160;&#177;&#160;SE)   Basal cell lines (A) 0.12&#160;&#177;&#160;0.03 1.11&#160;&#177;&#160;0.29 6.92&#160;&#177;&#160;1.23 0.03&#160;&#177;&#160;0.01  Luminal cell lines (B) 0.34&#160;&#177;&#160;0.08 0.54&#160;&#177;&#160;0.16 30.98&#160;&#177;&#160;10.04 0.09&#160;&#177;&#160;0.02  t-test A versus B P&#160;=&#160;0.01 P&#160;=&#160;0.09 P&#160;=&#160;0.02 P&#160;=&#160;0.01  ER+ cell lines (C) 0.40&#160;&#177;&#160;0.10 0.64&#160;&#177;&#160;0.20 39.73&#160;&#177;&#160;15.39 0.12&#160;&#177;&#160;0.04  ER&#8722; cell lines (D) 0.15&#160;&#177;&#160;0.04 0.90&#160;&#177;&#160;0.22 9.42&#160;&#177;&#160;1.83 0.03&#160;&#177;&#160;0.01  ER&#8722; Luminal cell lines (E) 0.23&#160;&#177;&#160;0.14 0.36&#160;&#177;&#160;0.26 15.68&#160;&#177;&#160;5.46 0.04&#160;&#177;&#160;0.02  t-test C versus D P&#160;=&#160;0.02 P&#160;=&#160;0.39 P&#160;=&#160;0.05 P&#160;=&#160;0.03  t-test C versus E P&#160;=&#160;0.27 P&#160;=&#160;0.39 P&#160;=&#160;0.15 P&#160;=&#160;0.06  t-test D versus E P&#160;=&#160;0.47 P&#160;=&#160;0.06 P&#160;=&#160;0.13 P&#160;=&#160;0.38  HER2+ cell lines (F) 0.27&#160;&#177;&#160;0.11 0.28&#160;&#177;&#160;0.11 38.69&#160;&#177;&#160;18.58 0.09&#160;&#177;&#160;0.04  HER2&#8722; cell lines (G) 0.22&#160;&#177;&#160;0.05 1.02&#160;&#177;&#160;0.21 11.86&#160;&#177;&#160;1.92 0.05&#160;&#177;&#160;0.01  HER2+ Luminal cell lines (H) 0.27&#160;&#177;&#160;0.12 0.31&#160;&#177;&#160;0.14 43.54&#160;&#177;&#160;22.26 0.10&#160;&#177;&#160;0.05  HER2&#8722; Luminal cell lines (I) 0.35&#160;&#177;&#160;0.11 0.73&#160;&#177;&#160;0.26 20.35&#160;&#177;&#160;3.43 0.09&#160;&#177;&#160;0.02  t-test F versus G P&#160;=&#160;0.66 P&#160;=&#160;0.003 P&#160;=&#160;0.16 P&#160;=&#160;0.39  t-test F versus H P&#160;=&#160;0.99 P&#160;=&#160;0.86 P&#160;=&#160;0.86 P&#160;=&#160;0.86  t-test F versus I P&#160;=&#160;0.58 P&#160;=&#160;0.13 P&#160;=&#160;0.33 P&#160;=&#160;0.97  t-test G versus H P&#160;=&#160;0.71 P&#160;=&#160;0.006 P&#160;=&#160;0.17 P&#160;=&#160;0.35  t-test G versus I P&#160;=&#160;0.27 P&#160;=&#160;0.38 P&#160;=&#160;0.04 P&#160;=&#160;0.18  t-test H versus I P&#160;=&#160;0.60 P&#160;=&#160;0.16 P&#160;=&#160;0.30 P&#160;=&#160;0.86</text>
    </passage>
    <passage>
      <infon key="type">table_footnote</infon>
      <offset>23611</offset>
      <text>The table shows the associations between RAR&#945;1-4 and the Luminal versus Basal phenotype, ER positivity versus ER negativity, as well as HER2 positivity versus HER2 negativity. P-values for the indicated comparisons (Student's t-test) are shown.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>23860</offset>
      <text>We determined RAR&#946;1 expression and combined expression of RAR&#946;2 and 5, as the last two variants code for the same protein. RAR&#946;1 is the most abundant species, although the transcript is detectable only in 15 of 42 cell lines (Supplementary Fig S6A). Despite regulation by distinct promoters, RAR&#946;1 and RAR&#946;2/5 are always co-expressed (Supplementary Fig S6B). Both RAR&#946;1 and RAR&#946;2/5 are over-expressed in Basal relative to Luminal cells. The same is true in ER&#8722; versus ER+ cell lines, even if the analysis is restricted to the Luminal/ER&#8722; group (Supplementary Fig S6C). Regarding possible associations with ATRA sensitivity, no significant difference in the levels of RAR&#946;1 or RAR&#946;2/5 between the T1 and T3 cell lines is evident before or after stratification for the Luminal/Basal phenotype (Fig6B).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>24687</offset>
      <text>As for RAR&#947;, we focused our attention on RAR&#947;1-3, which are predicted to code for active transcription factors. The order of expression for the RAR&#947; forms is RAR&#947;1&#160;&gt;&gt;&#160;RAR&#947;2&#160;&gt;&#160;RAR&#947;3 (Supplementary Fig S7A). Consistent with regulation by the same promoter, only the RAR&#947;2/RAR&#947;3 couple is characterized by co-regulation across all the cell lines (Supplementary Fig S7B). As the RAR&#946; variants, RAR&#947;2 and RAR&#947;3 show a direct association with the Basal and ER&#8722; phenotypes (Supplementary Fig S7C), while only RAR&#947;3 is significantly higher in HER2&#8722; than HER2+ cells. In addition, RAR&#947;2 and RAR&#947;3 tend to be over-expressed in the T3 relative to the T1 group (Fig6B), supporting the idea that they represent negative factors in terms of ATRA sensitivity (Bosch et&#160;al, 2012).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>25507</offset>
      <text>Taken together, the results point to RAR&#945;3 as the principal element of the retinoid pathway mediating the anti-proliferative responses of Luminal cells to ATRA.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>25672</offset>
      <text>RAR&#945;3 as a major player of ATRA sensitivity in primary tumors</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>25738</offset>
      <text>The profiles of expression of the RAR splicing variants were defined in the primary tumors used to evaluate ATRA sensitivity (see Fig3). In all the specimens considered, RAR&#945;3 and RAR&#945;2 are the most abundant RAR&#945; mRNAs and have a similar level of expression (Fig7A), which is different from what is observed in the cell lines. Across all the samples, RAR&#946;1 is more abundant than RAR&#946;2, although RAR&#946;1 levels are at least one order of magnitude lower than the RAR&#945;3/RAR&#945;2 counterparts. In the case of the RAR&#947; variants, RAR&#947;1 and RAR&#947;2 show intermediate levels of expression relative to RAR&#945;3/RAR&#945;2 and RAR&#946;1/RAR&#946;2. RAR&#947;2 in primary tumors is more abundant than expected from the cell-line results, while RAR&#947;3 is by far the least abundant species. The expression of RAR&#945;3/RAR&#945;1, RAR&#945;3/RAR&#945;2, RAR&#945;3/RAR&#945;4, RAR&#945;2/RAR&#945;4, RAR&#947;1/RAR&#947;2, RAR&#947;1/RAR&#947;3, and RAR&#947;2/RAR&#947;3 across the tumor samples is highly correlated (Supplementary Fig S8).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>26787</offset>
      <text>Basal levels of RAR&#945;, RAR&#946;, and RAR&#947; mRNA splicing variants in mammary tumors</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>26876</offset>
      <text> Each value represents the mean&#160;&#177;&#160;SD of two replicate measurements. The table shows the statistical significance of the indicated comparisons. *Significantly different (P-value&#160;&lt;&#160;0.05, Student's t-test). **Significantly different (P-value&#160;&lt;&#160;0.01, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>27150</offset>
      <text> The plots illustrate the average expression levels of the indicated mRNAs (mean&#160;&#177;&#160;SD of two replicates) in tumor samples classified as ATRA-sensitive (Sens) and ATRA-resistant (Res) according to the response of Ki67. *Significantly different (P-value&#160;&lt;&#160;0.05, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>27435</offset>
      <text>Total RNA was extracted from the tissue slices deriving from the surgical specimens of breast cancer patients used in Fig3 before any treatment with DMSO or ATRA. RNA was subjected to RT&#8211;PCR analysis to determine the basal expression of the indicated RAR splicing variants.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>27711</offset>
      <text>As for possible associations between RAR splicing variants and tumor cell phenotype, in accordance with the cell-line data, the content of RARa3 is generally higher in Luminal, relative to TN cancers and HER2+ tumors with no co-amplification of the ERBB2 and RARA loci (Fig7A). In the case of the RAR&#946; variants, expression is similar in the tissue samples and cell lines, as the average levels of RAR&#946;1 are significantly more abundant in TN (Basal) than in all the other tumor sub-types (Fig7A). In terms of possible associations between RAR splicing variants and ATRA sensitivity, only the levels of RAR&#945;3 are significantly higher in sensitive than in refractory tumors (Fig7B).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>28401</offset>
      <text>In conclusion, the complement of RAR splicing variants in breast tumors and derived cell lines is not entirely superimposable. Nevertheless, the profiles of RAR splicing variants in our cohort of mammary tumors support a major role of RAR&#945;3 in the anti-tumor responses to ATRA, which is in line with the conclusions drawn in cell lines.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>28742</offset>
      <text>RAR&#945; protein and ATRA sensitivity in breast cancer cell lines</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>28808</offset>
      <text>Given the observed relevance of the RAR&#945;3 transcript in our models, the basal levels of the corresponding RAR&#945; protein were determined in breast cancer cell lines with a specific antibody (Fig8A and B). The average levels of RAR&#945; are significantly higher in T1 versus T3 ATRA score groups (Fig8C), and the same trend is observed if the analysis is restricted to Luminal cells. Larger amounts of RAR&#945; are also observed in Luminal versus Basal and ER+ versus ER&#8722; cell lines. As for possible correlations with the RAR&#945; mRNA variants across the cell lines, the highest R2 values were calculated for the RAR&#945; protein and the RAR&#945;3/RAR&#945;4 mRNAs (Fig8D). This indicates that the protein is encoded by either the RAR&#945;3 or the RAR&#945;4 transcript. Given the low relative expression levels of RAR&#945;4, we favor RAR&#945;3.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29658</offset>
      <text>RAR&#945; protein and ATRA sensitivity in breast cancer cell lines</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>29724</offset>
      <text> The panel illustrates representative Western blots for a number of cell lines. The blots were sequentially developed with RAR&#945;-specific and control tubulin antibodies. The positions of the RAR&#945; and tubulin bands (right) along with the position of a relevant molecular weight marker (left) are indicated. To normalize the Western blot signals in different gels, the same preparation of RAR&#945;-transfected COS-7 cell extracts (COS-7) and MCF7 extracts was loaded in each gel. The blots are representative of at least two independent experiments providing similar results. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>30306</offset>
      <text> The quantitative results obtained after densitometric analysis of the RAR&#945; bands are plotted against the ATRA scores. Cell lines are grouped according to the ATRA score (A&#8211;D groups and T1&#8211;T3 tertiles). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>30515</offset>
      <text> Left: The upper graph indicates the averages expression levels of the RAR&#945; protein in T1&#8211;T3 cell lines. The middle and lower graphs indicate the average expression levels after stratification of the cell lines for the Luminal (six cell lines in each of the T1 and T3 groups) and the Basal (six cell lines in each of the T1 and T3 groups) phenotype, respectively. Right: The levels of the RAR&#945; protein in Basal and Luminal cell lines (upper graph), in ER+, ER&#8722;, and Luminal ER&#8722; cell lines (middle graph) and the indicated classes of HER2+ and HER2&#8722; cell lines (lower graph) are shown. *Significantly different (P-value&#160;&lt;&#160;0.05, Student's t-test). **Significantly different (P-value&#160;&lt;&#160;0.01, Student's t-test). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>31238</offset>
      <text> The plots show the correlation curves between the levels of the indicated RAR&#945;-variant transcripts and the RAR&#945; protein. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>31369</offset>
      <text>Total proteins were extracted from logarithmically growing cell lines and subjected to Western blot analysis.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>31479</offset>
      <text>Effects of RAR agonists/antagonists in breast cancer cells</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>31538</offset>
      <text>The functional role of RAR&#945; in the anti-proliferative action of ATRA was evaluated in Luminal and Basal cell lines with different ATRA scores and RAR-variant expression profiles (Fig9) with a pharmacological approach, using the validated (Supplementary Fig S9) AM580 RAR&#945; agonist (Gianni et&#160;al, 1996), the UVI2003 RAR&#946; agonist (Alvarez et&#160;al, 2014), and the BMS961 RARA&#947; agonist (Gianni et&#160;al, 1993). The cell lines were challenged with increasing concentrations of ATRA, AM580, UVI2003, and BMS961 for 3 (data not shown) and 6&#160;days prior to evaluation of cell growth. In the ATRA-sensitive Luminal lines, AM580 is the only agonist which inhibits growth in a dose-dependent manner. In ER+/HER2&#8722; HCC-1428 cells, AM580 is more effective than ATRA, while the opposite is true in the ER&#8722;/HER2&#8722; EVSAT counterpart. In the remaining Luminal lines, AM580 and ATRA show similar efficacy. AM580 is also the sole agonist inhibiting the growth of the retinoid-sensitive Basal cell lines, HCC-1599, MDA-MB157, and HCC-1954. In these cellular contexts, no significant difference in the anti-proliferative activity of AM580 and ATRA is noticeable. AM580, UVI2003, BMS961, and ATRA are equally ineffective in retinoid-resistant HCC-38 cells.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>32779</offset>
      <text>Effects of RAR agonists on the growth of Luminal and Basal breast cancer cell lines</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>32863</offset>
      <text>The indicated Luminal and Basal cell lines were challenged with increasing concentrations of ATRA, the RAR&#945; agonist, AM580, the RAR&#946; agonist, UVI2003, and the RAR&#947; agonist,&#160;BMS961, for 6&#160;days. The complement of RAR-variant transcripts expressed in each cell line is shown in the left bar graphs (mean&#160;&#177;&#160;SD of two replicate measurements). The growth curves (sulforhodamine assay) of the cell lines are illustrated by the right linear plots. The results are expressed in % values relative to the corresponding control dishes treated with vehicle alone (right graphs). Each result is the mean&#160;&#177;&#160;SD of five replicate wells. ATRA sc&#160;=&#160;ATRA score.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>33518</offset>
      <text>To corroborate the results obtained with the RAR agonists, we evaluated the effects of the RAR&#945; antagonist, ER50891 (Kikuchi et&#160;al, 2001; Somenzi et&#160;al, 2007), and the RAR&#946;/&#947; antagonist, CD2665 (Szondy et&#160;al, 1997), on ATRA-dependent growth inhibition of HCC-1428 and SKBR3 cells, which are characterized by very high ATRA scores. To obtain maximal blockade of the two RARs without off-target effects, cells were treated with 100&#160;nM ATRA and 3&#160;&#956;M of ER50891 or CD2665, as this concentration of the antagonists blocks&#160;the trans-activating potential of ATRA in a RAR&#945;- and RAR&#946;/&#947;-specific fashion, respectively (Supplementary Fig S10). In HCC-1428 and SKBR3 cells, only ER50891 blocks the anti-proliferative action of ATRA (Supplementary Fig S11).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>34287</offset>
      <text>RAR&#945; and ATRA sensitivity: over-expression and knock-down studies</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>34357</offset>
      <text>To obtain direct proof that the RAR&#945;3 protein is mediating the action of ATRA, we over-expressed it in retinoid-resistant, HER2+/ER&#8722;, and Luminal MDA-MB453 cells. Two RAR&#945;-over-expressing (RARA-C5 and RARA-C7), two vector-transfected control (Vect-C1 and Vect-C2) clones, and the parental MDA-MB453 cells (WT) were used in comparative experiments. WT, Vect-C1, and Vect-C2 express barely detectable levels of the RAR&#945; protein, while large amounts of the product are synthesized by RARA-C5 and RARA-C7 cells (Fig10A). RARA-C5 and RARA-C7 express a transcriptionally active RAR&#945; form, as indicated by ATRA-dependent activation of the luciferase-based retinoid reporter, DR5-RARE-Luc. Over-expression of RAR&#945; does not exert major effects on the basal growth rate of the MDA-MB-453 clones (Fig10B). Upon treatment with increasing concentrations of ATRA for 3, 6, and 9&#160;days, Vect-C1 and Vect-C2 and WT cells are equally unresponsive to retinoid-dependent growth inhibition (Fig10C). In contrast, RARA-C5/RARA-C7 proliferation is inhibited dose-&#160;and time-dependently by ATRA. Thus, stable over-expression of RAR&#945; renders MDA-MB-453 cells sensitive to the retinoid with an &#8764;4-fold increase in the calculated ATRA score at 9&#160;days.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>35605</offset>
      <text>Over-expression of RAR&#945;1/3 in ATRA-resistant MDA-MB453 cells and silencing of RAR&#945;1/3 in ATRA-sensitive SKBR3 cells</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>35729</offset>
      <text> A, D The indicated clones and the parental cell line (WT) were transiently transfected with the RARE-DR5-Luc retinoid reporter construct and the level of luciferase activity was measured 24&#160;h after treatment with vehicle (DMSO) and ATRA (100&#160;nM), as illustrated in the upper bar graph. Each value is the mean&#160;&#177;&#160;SD of three replicate cultures. The levels of the RAR&#945; protein measured in the indicated clones by Western blot analysis is shown under the bar graph. To demonstrate that similar levels of total proteins were loaded in each lane, the &#946;-actin band signal obtained after re-blotting of the gel is shown. FI&#160;=&#160;Fluorescence intensity. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>36382</offset>
      <text> B, E The panels illustrate the growth curves of the indicated MDA-MB453 and SKBR3 clones and the SKBR3 parental cell lines (WT) measured with the sulforhodamine assay. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>36552</offset>
      <text> C The bar graphs illustrate the effect of increasing concentrations of ATRA on the growth of the indicated MDA-MB453 clones and the parental cell line. The cell lines were challenged with vehicle (DMSO) or ATRA for 3, 6, and 9 days prior to the sulforhodamine assay. OD&#160;=&#160;optical density at 540&#160;nm. Each value is the mean&#160;&#177;&#160;SD of five replicate culture wells. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>36920</offset>
      <text> F The graphs illustrate the effect of increasing concentrations of ATRA on the growth of the indicated SKBR3 clones and the parental cell line. The cell lines were challenged with vehicle (DMSO) or ATRA for 3 and 6&#160;days prior to the sulforhodamine assay. Each value is the mean&#160;&#177;&#160;SD of five replicate culture wells. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>37242</offset>
      <text> G The panel illustrates the effects exerted by ATRA (0.1&#160;&#956;M) on random cell motility of the indicated MDA-MB453 and SKBR3 clones. The results are representative of two independent experiments. Each value is the mean&#160;&#177;&#160;SE of the motility of at least 60 cells. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>37508</offset>
      <text>A RAR&#945;1/3 plasmid construct and the corresponding control void vector were stably transfected into ATRA-resistant MDA-MB453 cells. Two cell clones over-expressing RAR&#945; (RARA-C5 and RARA-C7) and two appropriate control clones (Vect-C1 and Vect-C2) were isolated. A RAR&#945;3 shRNA plasmid construct and the corresponding void vector were stably transfected into ATRA-sensitive SKBR3 cells. After selection, two cell clones silenced for RAR&#945;3 (RARA-sh18 and RARA-sh19) and two appropriate control clones&#160;(Vect-C6 and Vect-C8) were isolated.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>38059</offset>
      <text>Data information: * and **, significantly different from the corresponding vehicle-treated control (*P-value&#160;&lt;&#160;0.05, **P-value&#160;&lt;&#160;0.01, Student's t-test).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>38217</offset>
      <text>In a mirror series of experiments, we knocked down RAR&#945; in the retinoid-sensitive HER2+/ER&#8722; and Luminal SKBR3 cells by stable transfection of a RAR&#945;1/3-targeting shRNA. The two shRNA-transfected RARA-sh18 and RARA-sh19 clones express &lt;&#160;10% of the RAR&#945; protein levels in the parental (data not shown) and void vector-transfected Vect-C6 or Vect-C8 cells (Fig10D). Transfection of DR5-RARE-Luc in RARA-sh18 and RARA-sh19 cells demonstrates inhibition of ATRA-dependent transcriptional activity relative to the Vect-C6 or Vect-C8 counterparts (Fig10D). While the shRNA constructs and void vectors do not alter the basal growth rate of&#160;SKBR3 cells (Fig10E), RAR&#945; knockdown attenuates the anti-proliferative action of ATRA (Fig10F). Attenuation is observed at concentrations of ATRA between 0.001 and 0.1&#160;&#956;M and tends to be lost at the two highest concentrations considered, where ATRA exerts off-target effects.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>39142</offset>
      <text>We evaluated whether modulation of RAR&#945; has any effect on ATRA-dependent expression of four direct retinoid target genes. ATRA-dependent induction of CYP26A1, CYP26B1, BTG2, and RARRES3 is not observed in Vect-C2 cells (Supplementary Fig S12A). In contrast, ATRA induces the expression of the first three transcripts in RARA-C5 cells. Similar differential effects are observed if the levels of the two retinoid-dependent epithelial differentiation markers, &#946;-catenin and SMAD3 (Paroni et&#160;al, 2012), are measured in Vect-C1, Vect-C2, RARA-C5, and RARA-C7 cells before and after treatment with ATRA (Supplementary Fig S12B). Conversely, ATRA-dependent induction of the CYP26A1, CYP26B1, BTG2, and RARRES3 mRNAs as well as the &#946;-catenin and SMAD3 proteins observed in Vect-C8 cells is blocked in RARA-Sh18 cells. Thus, RAR&#945; is the predominant mediator not only of the anti-proliferative, but also of the transcriptional effects afforded by ATRA in the two breast cancer cells.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40130</offset>
      <text>To determine whether RAR&#945; mediates other ATRA-dependent responses of relevance for the anti-tumor activity of the retinoid, we measured single-cell random motility, as the process is a determinant of invasive/metastatic behavior and it is inhibited by ATRA in breast cancer cells (Terao et&#160;al, 2011). As expected from the results in parental lines (data not shown), MDA-MB453-derived Vect-C1 cells are unresponsive to the anti-motility action of ATRA (Fig10G), while SKBR3-derived Vect-C6 cells respond with a significant reduction in random motility. RAR&#945; over-expression sensitizes RARA-C5 and RARA-C7 cells to ATRA, while RAR&#945; knockdown induces ATRA resistance in RARA-sh18 and RARA-sh19 cells. These data support a key role of RAR&#945; in mediating the anti-metastatic activity of ATRA.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>40933</offset>
      <text>Identification of gene sets associated with ATRA sensitivity</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>40994</offset>
      <text>Besides RAR&#945;, other gene products are likely to play a role in the anti-tumor action of ATRA. Thus, we looked for genes whose basal levels of expression are correlated to the ATRA score across our panel of cell lines using the microarray/RNA-seq databases and a regressed Random Forest approach (Supplementary Fig S13). The goal was the generation of ranked lists of genes associated with ATRA sensitivity based on the variable importance scores (Supplementary Table S4).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>41470</offset>
      <text>We generated two distinct expression heat-maps of the top 100 RNA-seq (Fig11, left) and microarray (Fig1, right) genes associated with ATRA sensitivity in the two databases. Fourteen of the genes are common to the microarray and RNA-seq gene sets. This is a high proportion considering the large difference in the quantifiable gene products between the two datasets (RNA-seq&#160;=&#160;57,789; microarray&#160;=&#160;15,543). Cluster analysis of both the microarray and RNA-seq data allows a clear separation of the lines belonging to the T1 and T3 groups identified by the ATRA score. Although our gene sets may contain elements specific to Luminal or Basal cell lines, as indicated by the presence of three PAM50 genes (estrogen receptor 1,&#160;ESR1; progesterone receptor, PGR; CXXC finger protein 5, CXXC5), it must be noticed that they do not simply stratify the cell lines according to the Luminal or Basal phenotype. To validate the expression results with an independent assay, we performed quantitative real-time PCR on 14 selected genes. The PCR, microarray, and RNA-seq results are concordant (Supplementary Fig S14).</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>42581</offset>
      <text>Gene sets associated with ATRA sensitivity</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>42624</offset>
      <text>Using the microarray and RNA-seq data associated with the breast cancer cell lines, two ATRA score-associated gene lists ranked for their variable importance were generated.&#160;Upper Panels: The gene-expression results of the first 100-ranking genes in the RNA-seq (left) and microarray (right) datasets were used to perform a cluster analysis of the breast cancer cell lines according to the gene-expression profiles. Data are expressed using a log2 scale of the expression signal intensity after normalization of&#160;the data across the different cell lines. The genes marked in red are present in both the microarray and the RNA-seq gene sets. The cell lines marked in red are those belonging to the ATRA score T1 group and are sensitive to ATRA, while the ones marked in blue belong to the T3 group and are refractory to the retinoid. The left dark blue lines indicate the genes with higher levels of constitutive expression in the ATRA-sensitive cell lines, while the light blue lines indicate the genes with higher levels of basal expression in the ATRA-refractory cell lines. Lower Panels: The box plots show the enrichment score (single sample Gene Set Enrichment Analysis, ssGSEA) of the microarray (left) and RNA-seq (right) gene sets in the TN (patients 9, 22, 23, 31, 50) and Lum (patients 13, 18, 27, 36, 41, 44, 55, 60, 61, 62, 64) tumors cultured in the absence of ATRA for 48&#160;h. The P-values of the enrichment are indicated.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>44061</offset>
      <text>By far the highest ranking retinoid nuclear receptor in the list generated from the microarray data is RAR&#945;, standing within the first 3.6% of the ranked mRNAs. RAR&#945; is also highly ranked in the RNA-seq list (top 16.5%). Some of the 100 top-ranking genes present in both lists may be of interest for the anti-tumor action of ATRA. For instance, CXXC5 is a retinoid-inducible gene (Knappskog et&#160;al, 2011; Astori et&#160;al, 2013), and it mediates the proliferative responses of IGFs and HER2 in breast cancer (Montero et&#160;al, 2011, 2013). The ATRA-regulated SYT7 (Synaptotagmin-VII) (Ekici et&#160;al, 2008) and VAMP3 (vesicle-associated-membrane protein-3) proteins control the homeostasis of micro-vesicles, which, in turn, regulate mammary tumorigenesis (Wright et&#160;al, 2009). A splicing variant of CPE (carboxypeptidase-E) stimulates growth, and it is a biomarker for mammary tumor metastatic spread (Lee et&#160;al, 2011). In IRAK1 (interleukin-1-receptor-associated kinase-1) knockout macrophages, RAR&#945; expression is higher than in the parental counterparts (Maitra et&#160;al, 2009).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>45141</offset>
      <text>The two identified gene sets may be useful for the stratification of patients who are likely to benefit from retinoid-based therapeutic approaches. We evaluated whether primary Luminal tumors, which are generally responsive to the anti-proliferative action of ATRA, are enriched for elements present in both gene sets (Fig1, bottom), comparing the 11 Luminal and 5 TN tumors used to assess the genomic effects of ATRA (see Fig2). The enrichment (single sample Gene Set Enrichment Analysis, ssGSEA) of genes whose basal levels of expression is higher in ATRA-sensitive (T1 group) than in ATRA-refractory (T3 group) cell lines is significantly higher in Luminal relative to TN tumors. In contrast, the enrichment of genes whose basal levels of expression is lower in the T1 than in the T3 group tends to be lower in Luminal than TN tumors. The two identified gene sets are the basis for the generation of an optimized gene signature predictive of ATRA sensitivity.</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>46104</offset>
      <text>ATRA-dependent perturbations of the transcriptome in primary tumors</text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>46172</offset>
      <text> The heat-map shows the genes significantly up- or down-regulated by ATRA (P&#160;&lt;&#160;0.005, paired t-test) in either Luminal-A and&#160;-B (Lum) or triple-negative (TN) tumors, and the results are expressed as the log2 ratio observed between the ATRA and vehicle-treated samples. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>46445</offset>
      <text> A Venn diagram of the genes up- or down-regulated by ATRA in TN and Lum tumors is shown. The number of genes commonly or selectively regulated in TN and Lum tumors is indicated. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>46625</offset>
      <text> The heat-map shows the regulation patterns of the retinoid-dependent genes significantly modulated by ATRA (P&#160;&lt;&#160;0.001) in either TN or Lum tumors. The symbols highlighted in red represent the five genes differentially and significantly regulated by ATRA in Lum versus TN tumors. </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>46908</offset>
      <text> The panel shows the estrogen-receptor (ESR1) pathway, which is significantly enriched for genes regulated by ATRA in Lum tumors. The green arrows indicate up-regulatory or stimulating interactions, while the red arrows indicate down-regulatory or inhibitory interactions. The gray arrows indicate unknown types of interactions. The red and blue dots above the protein symbols indicate the effect of ATRA in Lum tumors (red&#160;=&#160;up-regulation; blue&#160;=&#160;down-regulation). </text>
    </passage>
    <passage>
      <infon key="type">fig_caption</infon>
      <offset>47379</offset>
      <text>Tissue slices corresponding to the indicated patients were treated with vehicle (DMSO) or ATRA (0.1&#160;&#956;M) for 48&#160;h. Whole-genome gene expression studies were performed on the extracted total RNA using a microarray platform.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>47604</offset>
      <text>Transcriptional responses to ATRA in short-term cultures of mammary tumors</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>47679</offset>
      <text>The results obtained in the cell lines and the short-term cultures of primary tumors support the concept that Luminal and ER+ phenotypes are positive determinants, while Basal and ER&#8722; phenotypes are negative determinants of sensitivity to the anti-proliferative action of ATRA. To evaluate the transcriptional effects of the retinoid, we performed microarray gene-expression studies in 16 of the 45 primary-tumor samples profiled with the Ki67 biomarker (see Fig3). The cohort analyzed consisted of 11 Luminal and 5 TN cases. Microarray data were validated by quantitative PCR on a selected number of tumors and genes (CYP26A1, CYP26B1, RARRES3, and BTG2) (Supplementary Fig S15).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>48362</offset>
      <text>ATRA exerts major quantitative effects on the transcriptomes not only of Luminal/ER+ tumors, but also of TN cancers (Fig12A and Supplementary Table S5). Cluster analysis of the regulated transcripts results in a clear separation between Luminal/ER+ and TN tumors on the basis of the genomic responses to ATRA. It is interesting to notice that cluster analysis groups together the three Ki67-unresponsive Luminal/ER+ cases (Patients No. 41, 55 and 61). A total of 1,702 genes are significantly regulated by ATRA (P&#160;&lt;&#160;0.005, paired t-test) in either TN or Luminal/ER+ tumors. Approximately 20% of the genes (up-regulated genes&#160;=&#160;198; down-regulated genes&#160;=&#160;134) are similarly modulated by ATRA in both the Luminal/ER+ and TN cases (Fig2B).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>49106</offset>
      <text>We focused our attention on the subset of genes identified as retinoid targets in various cell types (Balmer &amp; Blomhoff, 2002, 2005; Topletz et&#160;al, 2015). Among these 402 genes, 34 are significantly up- or down-regulated by ATRA (P&#160;&lt;&#160;0.001, paired t-test) in tissue slices derived from either Luminal/ER+ or TN tumors (Fig2C). Five of these genes are differentially regulated in Luminal/ER+ and TN tumors. The up-regulation of RARRES3 (retinoic acid receptor responder 3), TGM2 (transglutaminase 2), S100A8 (S100 calcium binding protein A8), and CYP26A1 (cytochrome P-450 26A1) is significantly higher in Luminal/ER+ tumors. In contrast, THBD (thrombomodulin) is significantly up-regulated only in TN tumors. RARRES3 up-regulation in Luminal/ER+ may play a role in the anti-motility and anti-metastatic effects of ATRA (Nwankwo, 2002; Terao et&#160;al, 2011), as the factor has been shown to suppress metastases to the lung in breast cancer (Errico, 2014; Morales et&#160;al, 2014). In contrast, increased induction of CYP26A1 may be detrimental for the anti-tumor action of ATRA, as the enzyme metabolizes and inactivates the retinoid (Thatcher et&#160;al, 2010; Topletz et&#160;al, 2012).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>50284</offset>
      <text>To define the biochemical pathways regulated by ATRA and potentially involved in the anti-tumor action of the retinoid, we performed gene-network enrichment analysis of the microarray data, focusing on Luminal/ER+ tumors. Among the top 10 processes enriched (Supplementary Table S6), the ER nuclear signal transduction pathway is of interest for its role in Luminal breast cancer growth. For instance, down-regulation of IRS1 and one of the&#160;regulatory subunit of PI3K by ATRA are likely to block the proliferation of Luminal/ER+ tumors caused by the growth factors IGF1 and EGF. Out of the 28 types of interactions between couples of proteins belonging to the ER pathway (Supplementary Table S7), 17 are consistent with an inhibition of the ER pathway by ATRA. Taken together, the data demonstrate an anti-estrogenic action of the retinoid in primary tumors, which is in line with what was reported in breast cancer cell lines (Hua et&#160;al, 2009).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>51232</offset>
      <text>We performed an interactome analysis (Fig12D) looking for gene products significantly over-connected in the network modulated by ATRA in Luminal/ER+ tumors. We focused on two groups of genes relevant for the molecular mechanisms underlying the anti-tumor action of ATRA, that is, transcription factors and kinases (Supplementary Table S8). As for transcription factors, the list of over-connected genes contains RARA, RARG, and RXRA. The presence of ESR1 and ESR2 among the top-ranked transcription factors is in line with the process enrichment analysis described above. Finally, the inclusion of STAT1, STAT5B, and STAT3 is of relevance given the cross talk between retinoid receptors and this group of transcription factors in acute myeloid leukemias (Gianni et&#160;al, 1997). As for the kinases, PI3K and AKT stand out, as ATRA has been shown to inhibit the two corresponding signal transduction pathways in certain breast cancer cell lines (Paroni et&#160;al, 2012).</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>52197</offset>
      <text>Discussion</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>52208</offset>
      <text>Exploitation of the clinical potential of ATRA requires definition of the sensitive mammary tumor subtypes and the molecular determinants of this sensitivity. In this study, we examined the responsiveness of a large panel of breast cancer cell lines, recapitulating the heterogeneity of the disease, to the anti-proliferative action of ATRA. A Luminal phenotype and ER expression are identified as major determinants of ATRA sensitivity. In contrast, a Basal phenotype, which is characteristic of TN tumors, is associated with ATRA refractoriness. The observations made in cell lines reflect the situation delineated in primary tumors using short-term tissue-slice cultures. We propose that ATRA should be used in a neo-adjuvant or adjuvant setting for the treatment and chemoprevention of Luminal ER+ tumors. In ER+ breast cancer, ATRA may represent a rational addition to anti-estrogens particularly in conditions of induced resistance to these agents (Belosay et&#160;al, 2006; Johansson et&#160;al, 2013). Despite their importance, the Luminal/Basal phenotypes and ER positivity/negativity are not sufficient determinants of ATRA sensitivity or resistance. In fact, there is a minority of the Luminal or ER+ cell lines and tumors which are refractory to the retinoid and a few Basal cell lines and tumors responding to ATRA. This indicates that factors other than the cell origin control the responsiveness of breast cancer cells to this anti-tumor agent.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>53660</offset>
      <text>The results obtained in short-term tissue-slice cultures demonstrate that ATRA exerts major quantitative effects on the transcriptomes not only of Luminal/ER+ tumors, but also of TN cancers. Thus, our transcriptomic data support the concept that the general refractoriness of TN tumors and the corresponding Basal cell lines to the anti-proliferative action of ATRA is not associated with a similar resistance to the transcriptional effects of the retinoid. In contrast, it is likely that ATRA sensitivity of Luminal/ER+ relative to TN/Basal tumor cells is the consequence of different transcription programs activated by the retinoid in the two cell types. The different complement of RAR isoforms and splicing variants present in Luminal/ER+ relative to TN/Basal tumor cells may be at the basis of these differential responses to ATRA.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>54498</offset>
      <text>The biological activity of ATRA is deemed to be mediated by the RXR/RAR and RXR/PPAR&#946;/&#948; transcription factors via the distinct cytosolic binding proteins, CRABP2 and FABP5 (Shaw et&#160;al, 2003; Schug et&#160;al, 2007; Kannan-Thulasiraman et&#160;al, 2010). The correlative results obtained in cell lines and breast tumors indicate that expression of the RAR&#945;3 mRNA and the corresponding protein is directly associated with ATRA sensitivity, the Luminal phenotype, and ER positivity. The role of RAR&#945; in the anti-proliferative responses triggered by ATRA is supported by functional studies involving specific pharmacologic RAR agonists/antagonists performed in selected Luminal and Basal cell lines. RAR&#945; over-expression and knockdown experiments provide direct evidence for the involvement of the receptor not only in ATRA-dependent growth inhibition, but also in other aspects of ATRA anti-tumor activity. In addition, RAR&#945; is a biomarker of ATRA sensitivity and the major target for retinoids in breast cancer. This suggests that specific RAR&#945; agonists should be developed for the management of the disease to avoid side effects and toxicity associated with the clinical use of a pan-RAR agonist like ATRA (Garattini et&#160;al, 2007b, 2014).</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>55752</offset>
      <text>Although RAR&#945; is an important mediator of ATRA anti-tumor activity, it is unlikely to represent the only determinant of sensitivity. The search for other genes outside the retinoid pathway performed in this study resulted in the definition of two gene sets whose basal expression levels are associated with retinoid sensitivity/resistance in our panel of cell lines. These gene sets are relevant from both a basic and an applied perspective. At the basic level, the two gene sets provide information on previously unrecognized genes and gene networks which may control/influence the sensitivity of cancer cells to ATRA. Our gene sets show a significant overlap (M. Bolis, unpublished observations) with the gene-expression signatures determined for PI3K-inhibitors (Daemen et&#160;al, 2013). This suggests that part of the anti-proliferative action of ATRA may involve inhibition of the PI3K pathway, which is often turned on in breast cancer cells. The contention is supported by the presence of PI3K among the over-connected kinases in the network of gene products modulated by ATRA in primary tumors challenged with ATRA ex&#160;vivo. With respect to this, a major link may be represented by PREX1 (RAC-exchanger-factor-1), an important determinant of the sensitivity of breast cancer cells to PI3K inhibitors (Ebi et&#160;al, 2013). Interestingly, combinations of PI3K inhibitors and ATRA show additive or synergistic growth effects in selected breast cancer cell lines (MT, unpublished results). At the applied level, the two gene sets contain possible pharmacological targets for the design of therapeutic combinations based on ATRA or derived retinoids. In addition, these gene sets have the potential to be optimized in view of their use as diagnostic tools for the selection of breast cancer patients who may benefit from retinoid-based treatments.</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>57599</offset>
      <text>In conclusion, this work is a first step toward a rational use of ATRA and derived retinoids in breast cancer. The data obtained with both the cell lines and the short-term tissue cultures indicate that &#8765;70% of Luminal breast cancers are likely to be responsive to ATRA. As ATRA is characterized by low toxicity as well as mild side effects, our data strongly suggest that the compound is of potential interest in the adjuvant therapy of the majority of Luminal breast cancer with particular reference to ER+ tumors. Indeed, the results obtained represent the rationale for an independent clinical trial (AZ and EG, personal communication), which we will conduct in post-menopausal patients suffering from ER+ breast cancer aimed at evaluating the efficacy of ATRA addition to aromatase inhibitors.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>58400</offset>
      <text>Materials and Methods</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>58422</offset>
      <text>Chemicals plasmids and cell lines</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>58456</offset>
      <text>The following compounds were used: ATRA (Sigma-Aldrich, https://www.sigmaaldrich.com), AM580 (Tocris, http://www.tocris.com), BMS961 (Tocris), ER50891 (Tocris), CD2665 (Tocris), and UVI2003 (a kind gift of Dr. Angel De Lera, Universidade de Vigo, Spain). Sulforhodamine was from Sigma-Aldrich Co. A list of the cell lines, their characteristics, and origin is available in Supplementary Table S1. The plasmid constructs used for RAR&#945;3 over-expression in MDA-MB453 cells and knockdown in SKBR3 cells are described below.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>58980</offset>
      <text>Plasmid construction</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>59001</offset>
      <text>To generate the RAR&#945; plasmid used for the over-expression in MDA-MB453 cells, 5&#8242; FLAG-tagged RAR&#945;1/3 cDNA was introduced into pcDNA3, using the NdeI and XhoI sites in the multiple cloning region downstream of the pCMV promoter. To obtain the RAR&#945; silencing construct, a custom-synthesized double-stranded DNA coding for a RAR&#945;-targeting shRNA (5&#8242;-GATCCGCGGGCACCTCAATGGGTACTTCCTGTCAGATACCCATTGAGGTGCCCGCTTTTTG-3&#8242;, the underlined sequence corresponds to nt 629&#8211;646 of the NM_001145301.2 sequence, Sigma-Aldrich) was introduced into the pGreenPuro plasmid (System Biosciences Inc., http://www.systembio.com), using the EcoRI and BamHI sites in the multiple cloning region downstream of the H1 gene promoter. The RAR&#945; over-expressing MDA-MB453 clones and the RARA-silenced SKBR3 clones were selected, after transfection with Fugene HD (Promega, www.promega.com), in the presence of 400&#160;&#956;g/ml G418 and 1&#160;&#956;g/ml puromycin (Sigma-Aldrich), respectively.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>59969</offset>
      <text>Short-term tissue slice cultures</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>60002</offset>
      <text>Tissue cultures of primary breast tumors were performed as described (van der Kuip et&#160;al, 2006). Briefly, tissue slices (thickness, 200&#160;&#956;m) deriving from surgical specimens of 45 breast cancer patients who underwent a diagnostic Tru-cut procedure were challenged with vehicle (DMSO) or ATRA (0.1&#160;&#956;M) for 48&#160;h in Mammary Epithelial Cell Growth Medium (Lonza, Allendale, NJ). At the end of the treatment, samples were fixed, paraffin-included, and dissected into 5-&#956;m slices, which were subjected to immuno-histochemical staining with an antibody targeting the Ki67 proliferation-associated marker. The percentage of Ki67-positive tumor cells in the various samples was assessed in a quantitative manner by automatic image analysis, and the results are illustrated. Scoring of Ki67 was blinded as to treatment. Each value represents the mean&#160;&#177;&#160;SE of at least five separate fields for each experimental sample. The fresh primary tumor samples used for the short-term tissue slice cultures aimed at assessing ATRA sensitivity were supplied by Fondazione S. Maugeri, Pavia. All the procedures were approved by the internal ethical committee of the Fondazione S.&#160;Maugeri, and an informed consent for the donation of the sample was obtained from patients.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>61262</offset>
      <text>ATRA score</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>61273</offset>
      <text>Cell lines were exposed to increasing concentrations of ATRA (0.001&#8211;10.0&#160;&#956;M) for 3, 6, and 9&#160;day, and cell growth was determined with sulforhodamine assays (Skehan et&#160;al, 1990; Voigt, 2005; Vichai &amp; Kirtikara, 2006). A detailed description of the ATRA scores and associated mathematical equations and models is available in Supplementary Methods.</text>
    </passage>
    <passage>
      <infon key="type">title_3</infon>
      <offset>61626</offset>
      <text>The paper explained</text>
    </passage>
    <passage>
      <infon key="type">title_4</infon>
      <offset>61646</offset>
      <text>Problem</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>61654</offset>
      <text>All-trans retinoic acid (ATRA) is the primary vitamin A metabolite and a promising agent in the treatment/chemoprevention of breast cancer. Breast cancer is very heterogeneous, being a collection of different diseases. A rational use of ATRA in breast cancer requires the definition of the sensitive subtypes and the molecular determinants underlying retinoid sensitivity.</text>
    </passage>
    <passage>
      <infon key="type">title_4</infon>
      <offset>62027</offset>
      <text>Results</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>62035</offset>
      <text>We examined ATRA sensitivity in a large panel of breast cancer cell lines, recapitulating the heterogeneity of the disease after development of a new parameter (ATRA score) defining ATRA sensitivity in a quantitative manner. Luminal and ER+ (estrogen-receptor-positive) cell lines are generally sensitive to ATRA. In contrast, refractoriness or low sensitivity is associated with a Basal phenotype and HER2 positivity. The associations between cellular phenotype and ATRA sensitivity are confirmed using short-term tissue-slice cultures of primary tumors, which also result in the definition of the modifications in the transcriptome afforded by ATRA in Luminal and Basal tumors. Using a retinoid-pathway-oriented approach, RAR&#945; is identified as the only member of the retinoid pathway directly associated with the Luminal phenotype, estrogen positivity, and ATRA sensitivity. Studies in selected Luminal and Basal cell lines with RAR-specific agonists/antagonists confirm that RAR&#945; is the principal mediator of ATRA responsiveness. In addition, RAR&#945; over-expression sensitizes ATRA-resistant cells to the retinoid. In contrast, RAR&#945; silencing in ATRA-sensitive cells abrogates the activity of the retinoid. All this is paralleled by similar effects on ATRA-dependent inhibition of cell motility, indicating that RAR&#945; mediates also ATRA anti-metastatic effects. Whole-genome gene-expression data allow the definition of two overlapping gene sets expressed in basal conditions and characterized by predictive potential and associated with ATRA sensitivity in breast cancer cell lines and tumors.</text>
    </passage>
    <passage>
      <infon key="type">title_4</infon>
      <offset>63650</offset>
      <text>Impact</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>63657</offset>
      <text>From a basic point of view, we provide information as to the breast cancer cellular phenotypes and the RAR isoform regulating ATRA sensitivity. In addition, we identify a first list of genes of functional relevance for the anti-tumor activity of ATRA and derived retinoids in breast cancer. From an applied perspective, the study provides fundamental information for the development of retinoid-based therapeutic strategies aimed at the stratified treatment of breast cancer. Finally, the data suggest that therapeutic strategies based on the use of RAR&#945;-specific retinoids may overcome the toxicity problems associated with the clinical use of a pan-RAR agonist like ATRA.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>64335</offset>
      <text>Xenotransplants of HCC-1599 cells</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>64369</offset>
      <text>HCC-1599 cells (1&#160;&#215;&#160;107/animal) were injected subcutaneously on both flanks of female 6-week-old SCID mice weighing &#8765;18&#160;g (Harlan Laboratories, http://www.harlan.com). All the experiments were performed following approval of the internal Ethical Committee on Animal Experimentation and were conducted in compliance with the Italian legislation. Tumor volume was determined with a caliper and by magnetic resonance imaging (MRI, Supplementary Methods).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>64827</offset>
      <text>PCR and Western blot analyses</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>64857</offset>
      <text>Real-time PCR was performed using Taqman assays (Terao et&#160;al, 2011). Amplimers and Taqman probes (Life Technologies Italia, Monza, Italy) are listed in Supplementary Methods. Western blots were performed with RAR&#945; (Gianni et&#160;al, 2012), &#946;-actin, tubulin, SMAD3 (Paroni et&#160;al, 2012), and &#946;-catenin (Paroni et&#160;al, 2012) antibodies.</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>65196</offset>
      <text>Gene-expression studies in short-term tissue cultures of primary tumors</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>65268</offset>
      <text>Tissue slices were incubated with vehicle (DMSO) or ATRA (0.1&#160;&#956;M) for 48&#160;h. Total RNA was extracted with the miRNeasy Mini kit (QIAGEN), labeled with the Lowinput Quick Amp labeling kit (Cy3 mono color, Agilent), and hybridized to whole-genome gene expression microarrays (Agilent). Fluorescent signals were determined and quantified with an Agilent microarray laser scanner. The microarray raw data and experimental protocols were deposited in the Arrayexpress database (accession No. E-MTAB-3313).</text>
    </passage>
    <passage>
      <infon key="type">title_2</infon>
      <offset>65771</offset>
      <text>Bioinformatic analysis of the gene-expression microarray and RNA-seq data</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>65845</offset>
      <text>Gene expression data for the cell lines were derived from the Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays (provided by CCLE, http://www.broadinstitute.org/ccle). RAW sequencing data (Illumina-paired end reads) were derived from two distinct datasets. The first dataset is publicly available in the CCLE project and. BAM files where downloaded through the cgdownload utility from the Cancer Genomics Hub (CGHub/UCSC, https://cghub.ucsc.edu). Sequencing data (.FASTQ files) for those cell lines that were not part of this first set were downloaded from a second GenBank dataset under the accession GSE48216 (GenBank). The heat-maps were generated using the algorithms available in T-Mev (http://www.tm4.org). Further details on the bioinformatic analyses performed on all the gene-expression data are available in the appropriate sections of the Supplementary Information.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>66726</offset>
      <text>Author contributions</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>66747</offset>
      <text>FC, GP, AZ, MG, and JNF performed the experimental work involving the use of cell lines; MB, MF, and LP were involved in the computational analysis of the gene-expression datasets; ML and PU developed the mathematical algorithms and models necessary for the development of the ATRA score; SKG, PR, and MFS performed the experiments and the analyses involved in the short-term tissue-slice cultures; MK performed all the experiments involving molecular biology expertise, MMB conducted the in&#160;vivo studies involving animal models; AZ and FP provided the surgical samples and performed some of the analyses on these samples; MT supervised all the phases of the work, designed many of the experiments in&#160;vitro, and wrote the manuscript; EG designed and supervised the entire study and wrote the manuscript.</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>67553</offset>
      <text>Conflict of interest</text>
    </passage>
    <passage>
      <infon key="type">paragraph</infon>
      <offset>67574</offset>
      <text>The authors declare that they have no conflict of interest.</text>
    </passage>
    <passage>
      <infon key="type">title</infon>
      <offset>67634</offset>
      <text>References</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Levy;given-names:CC</infon>
      <infon key="name_3">surname:Gaddis;given-names:S</infon>
      <infon key="name_0">surname:Abba;given-names:MC</infon>
      <infon key="name_1">surname:Hu;given-names:Y</infon>
      <infon key="name_6">surname:Hill;given-names:J</infon>
      <infon key="name_7">surname:Bissonnette;given-names:RP</infon>
      <infon key="name_4">surname:Kittrell;given-names:FS</infon>
      <infon key="name_5">surname:Zhang;given-names:Y</infon>
      <infon key="name_8">surname:Medina;given-names:D</infon>
      <infon key="name_9">surname:Brown;given-names:PH</infon>
      <infon key="volume">1</infon>
      <infon key="pub-id_pmid">18786257</infon>
      <infon key="source">BMC Med Genomics</infon>
      <infon key="fpage">40</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>67645</offset>
      <text>Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Guimaraes;given-names:AR</infon>
      <infon key="name_3">surname:Corcoran;given-names:RB</infon>
      <infon key="name_0">surname:Alagesan;given-names:B</infon>
      <infon key="name_1">surname:Contino;given-names:G</infon>
      <infon key="name_6">surname:Hezel;given-names:AF</infon>
      <infon key="name_7">surname:Wong;given-names:KK</infon>
      <infon key="name_4">surname:Deshpande;given-names:V</infon>
      <infon key="name_5">surname:Wojtkiewicz;given-names:GR</infon>
      <infon key="volume">21</infon>
      <infon key="name_8">surname:Loda;given-names:M</infon>
      <infon key="name_9">surname:Weissleder;given-names:R</infon>
      <infon key="lpage">404</infon>
      <infon key="pub-id_pmid">25348516</infon>
      <infon key="source">Clin Cancer Res</infon>
      <infon key="fpage">396</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>67770</offset>
      <text>Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Gronemeyer;given-names:H</infon>
      <infon key="name_3">surname:de Lera;given-names:AR</infon>
      <infon key="name_0">surname:Alvarez;given-names:R</infon>
      <infon key="name_1">surname:Vaz;given-names:B</infon>
      <infon key="source">Chem Rev</infon>
      <infon key="volume">114</infon>
      <infon key="lpage">125</infon>
      <infon key="pub-id_pmid">24266866</infon>
      <infon key="fpage">1</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>67841</offset>
      <text>Functions, therapeutic applications, and synthesis of retinoids and carotenoids</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Aloysius;given-names:TA</infon>
      <infon key="name_3">surname:Bullinger;given-names:L</infon>
      <infon key="name_0">surname:Astori;given-names:A</infon>
      <infon key="name_1">surname:Fredly;given-names:H</infon>
      <infon key="name_6">surname:Delhommeau;given-names:F</infon>
      <infon key="name_7">surname:Hagen;given-names:KM</infon>
      <infon key="name_4">surname:Mansat-De Mas;given-names:V</infon>
      <infon key="name_5">surname:de la Grange;given-names:P</infon>
      <infon key="volume">4</infon>
      <infon key="name_8">surname:Recher;given-names:C</infon>
      <infon key="name_9">surname:Dusanter-Fourt;given-names:I</infon>
      <infon key="lpage">1448</infon>
      <infon key="pub-id_pmid">23988457</infon>
      <infon key="source">Oncotarget</infon>
      <infon key="fpage">1438</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>67921</offset>
      <text>CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia</text>
    </passage>
    <passage>
      <infon key="volume">43</infon>
      <infon key="name_0">surname:Balmer;given-names:JE</infon>
      <infon key="name_1">surname:Blomhoff;given-names:R</infon>
      <infon key="source">J Lipid Res</infon>
      <infon key="lpage">1808</infon>
      <infon key="pub-id_pmid">12401878</infon>
      <infon key="fpage">1773</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>68045</offset>
      <text>Gene expression regulation by retinoic acid</text>
    </passage>
    <passage>
      <infon key="volume">96</infon>
      <infon key="name_0">surname:Balmer;given-names:JE</infon>
      <infon key="name_1">surname:Blomhoff;given-names:R</infon>
      <infon key="source">J Steroid Biochem Mol Biol</infon>
      <infon key="lpage">354</infon>
      <infon key="pub-id_pmid">16081280</infon>
      <infon key="fpage">347</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>68089</offset>
      <text>A robust characterization of retinoic acid response elements based on a comparison of sites in three species</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Njar;given-names:VC</infon>
      <infon key="volume">66</infon>
      <infon key="name_0">surname:Belosay;given-names:A</infon>
      <infon key="name_1">surname:Brodie;given-names:AM</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="lpage">11493</infon>
      <infon key="pub-id_pmid">17145897</infon>
      <infon key="fpage">11485</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>68198</offset>
      <text>Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells</text>
    </passage>
    <passage>
      <infon key="name_0">surname:Berry;given-names:DC</infon>
      <infon key="name_1">surname:Noy;given-names:N</infon>
      <infon key="source">PPAR Res</infon>
      <infon key="volume">2007</infon>
      <infon key="pub-id_pmid">18274629</infon>
      <infon key="fpage">73256</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>68310</offset>
      <text>Is PPARbeta/delta a retinoid receptor?</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Lu;given-names:Y</infon>
      <infon key="name_3">surname:Garcia;given-names:A</infon>
      <infon key="name_0">surname:Bosch;given-names:A</infon>
      <infon key="name_1">surname:Bertran;given-names:SP</infon>
      <infon key="name_6">surname:Farias;given-names:EF</infon>
      <infon key="name_4">surname:Jones;given-names:AM</infon>
      <infon key="name_5">surname:Dawson;given-names:MI</infon>
      <infon key="volume">14</infon>
      <infon key="pub-id_pmid">22920668</infon>
      <infon key="source">Breast Cancer Res</infon>
      <infon key="fpage">R121</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>68349</offset>
      <text>Reversal by RARalpha agonist Am580 of c-Myc-induced imbalance in RARalpha/RARgamma expression during MMTV-Myc tumorigenesis</text>
    </passage>
    <passage>
      <infon key="volume">10</infon>
      <infon key="name_0">surname:Chambon;given-names:P</infon>
      <infon key="source">FASEB J</infon>
      <infon key="lpage">954</infon>
      <infon key="pub-id_pmid">8801176</infon>
      <infon key="fpage">940</infon>
      <infon key="year">1996</infon>
      <infon key="type">ref</infon>
      <offset>68473</offset>
      <text>A decade of molecular biology of retinoic acid receptors</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Sukumar;given-names:S</infon>
      <infon key="volume">19</infon>
      <infon key="name_0">surname:Connolly;given-names:RM</infon>
      <infon key="name_1">surname:Nguyen;given-names:NK</infon>
      <infon key="source">Clin Cancer Res</infon>
      <infon key="lpage">1659</infon>
      <infon key="pub-id_pmid">23322901</infon>
      <infon key="fpage">1651</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>68530</offset>
      <text>Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Heiser;given-names:LM</infon>
      <infon key="name_3">surname:Wang;given-names:NJ</infon>
      <infon key="name_0">surname:Daemen;given-names:A</infon>
      <infon key="name_1">surname:Griffith;given-names:OL</infon>
      <infon key="name_6">surname:Pepin;given-names:F</infon>
      <infon key="name_7">surname:Durinck;given-names:S</infon>
      <infon key="name_4">surname:Enache;given-names:OM</infon>
      <infon key="name_5">surname:Sanborn;given-names:Z</infon>
      <infon key="name_8">surname:Korkola;given-names:JE</infon>
      <infon key="name_9">surname:Griffith;given-names:M</infon>
      <infon key="volume">14</infon>
      <infon key="pub-id_pmid">24176112</infon>
      <infon key="source">Genome Biol</infon>
      <infon key="fpage">R110</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>68649</offset>
      <text>Modeling precision treatment of breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Savoldi;given-names:GF</infon>
      <infon key="name_3">surname:Ferrari;given-names:F</infon>
      <infon key="name_0">surname:Di Lorenzo;given-names:D</infon>
      <infon key="name_1">surname:Gianni;given-names:M</infon>
      <infon key="name_4">surname:Albertini;given-names:A</infon>
      <infon key="name_5">surname:Garattini;given-names:E</infon>
      <infon key="volume">192</infon>
      <infon key="lpage">1072</infon>
      <infon key="pub-id_pmid">8507182</infon>
      <infon key="source">Biochem Biophys Res Commun</infon>
      <infon key="fpage">1066</infon>
      <infon key="year">1993</infon>
      <infon key="type">ref</infon>
      <offset>68695</offset>
      <text>Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Faber;given-names:AC</infon>
      <infon key="name_3">surname:Nishtala;given-names:M</infon>
      <infon key="name_0">surname:Ebi;given-names:H</infon>
      <infon key="name_1">surname:Costa;given-names:C</infon>
      <infon key="name_6">surname:Della Pelle;given-names:P</infon>
      <infon key="name_7">surname:Song;given-names:Y</infon>
      <infon key="name_4">surname:Kotani;given-names:H</infon>
      <infon key="name_5">surname:Juric;given-names:D</infon>
      <infon key="volume">110</infon>
      <infon key="name_8">surname:Yano;given-names:S</infon>
      <infon key="name_9">surname:Mino-Kenudson;given-names:M</infon>
      <infon key="lpage">21129</infon>
      <infon key="pub-id_pmid">24327733</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="fpage">21124</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>68820</offset>
      <text>PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Schuit;given-names:F</infon>
      <infon key="name_3">surname:Martinez-Serrano;given-names:A</infon>
      <infon key="name_0">surname:Ekici;given-names:M</infon>
      <infon key="name_1">surname:Hohl;given-names:M</infon>
      <infon key="name_4">surname:Thiel;given-names:G</infon>
      <infon key="source">J Biol Chem</infon>
      <infon key="volume">283</infon>
      <infon key="lpage">9268</infon>
      <infon key="pub-id_pmid">18234667</infon>
      <infon key="fpage">9257</infon>
      <infon key="year">2008</infon>
      <infon key="type">ref</infon>
      <offset>68894</offset>
      <text>Transcription of genes encoding synaptic vesicle proteins in human neural stem cells: chromatin accessibility, histone methylation pattern, and the essential role of rest</text>
    </passage>
    <passage>
      <infon key="name_0">surname:Errico;given-names:A</infon>
      <infon key="source">Nat Rev Clin Oncol</infon>
      <infon key="volume">11</infon>
      <infon key="pub-id_pmid">24913373</infon>
      <infon key="fpage">378</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>69065</offset>
      <text>Breast cancer: RARRES3-suppressing metastases to the lung in breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Terao;given-names:M</infon>
      <infon key="volume">75</infon>
      <infon key="name_0">surname:Garattini;given-names:E</infon>
      <infon key="name_1">surname:Gianni;given-names:M</infon>
      <infon key="source">Vitam Horm</infon>
      <infon key="lpage">354</infon>
      <infon key="pub-id_pmid">17368321</infon>
      <infon key="fpage">301</infon>
      <infon key="year">2007a</infon>
      <infon key="type">ref</infon>
      <offset>69140</offset>
      <text>Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Terao;given-names:M</infon>
      <infon key="volume">13</infon>
      <infon key="name_0">surname:Garattini;given-names:E</infon>
      <infon key="name_1">surname:Gianni;given-names:M</infon>
      <infon key="source">Curr Pharm Des</infon>
      <infon key="lpage">1400</infon>
      <infon key="pub-id_pmid">17506722</infon>
      <infon key="fpage">1375</infon>
      <infon key="year">2007b</infon>
      <infon key="type">ref</infon>
      <offset>69266</offset>
      <text>Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Garattini;given-names:SK</infon>
      <infon key="name_3">surname:Fratelli;given-names:M</infon>
      <infon key="name_0">surname:Garattini;given-names:E</infon>
      <infon key="name_1">surname:Bolis;given-names:M</infon>
      <infon key="name_6">surname:Gianni;given-names:M</infon>
      <infon key="name_7">surname:Zanetti;given-names:A</infon>
      <infon key="name_4">surname:Centritto;given-names:F</infon>
      <infon key="name_5">surname:Paroni;given-names:G</infon>
      <infon key="volume">40</infon>
      <infon key="name_8">surname:Pagani;given-names:A</infon>
      <infon key="name_9">surname:Fisher;given-names:JN</infon>
      <infon key="lpage">749</infon>
      <infon key="pub-id_pmid">24480385</infon>
      <infon key="source">Cancer Treat Rev</infon>
      <infon key="fpage">739</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>69420</offset>
      <text>Retinoids and breast cancer: from basic studies to the clinic and back again</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Terao;given-names:M</infon>
      <infon key="name_3">surname:Garattini;given-names:S</infon>
      <infon key="name_0">surname:Gianni;given-names:M</infon>
      <infon key="name_1">surname:Zanotta;given-names:S</infon>
      <infon key="name_4">surname:Garattini;given-names:E</infon>
      <infon key="source">Biochem Biophys Res Commun</infon>
      <infon key="volume">196</infon>
      <infon key="lpage">259</infon>
      <infon key="pub-id_pmid">8216300</infon>
      <infon key="fpage">252</infon>
      <infon key="year">1993</infon>
      <infon key="type">ref</infon>
      <offset>69497</offset>
      <text>Effects of synthetic retinoids and retinoic acid isomers on the expression of alkaline phosphatase in F9 teratocarcinoma cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Terao;given-names:M</infon>
      <infon key="name_3">surname:Guiso;given-names:G</infon>
      <infon key="name_0">surname:Gianni;given-names:M</infon>
      <infon key="name_1">surname:Li Calzi;given-names:M</infon>
      <infon key="name_6">surname:Rambaldi;given-names:A</infon>
      <infon key="name_7">surname:Garattini;given-names:E</infon>
      <infon key="name_4">surname:Caccia;given-names:S</infon>
      <infon key="name_5">surname:Barbui;given-names:T</infon>
      <infon key="volume">87</infon>
      <infon key="lpage">1531</infon>
      <infon key="pub-id_pmid">8608243</infon>
      <infon key="source">Blood</infon>
      <infon key="fpage">1520</infon>
      <infon key="year">1996</infon>
      <infon key="type">ref</infon>
      <offset>69624</offset>
      <text>AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Fortino;given-names:I</infon>
      <infon key="name_3">surname:LiCalzi;given-names:M</infon>
      <infon key="name_0">surname:Gianni;given-names:M</infon>
      <infon key="name_1">surname:Terao;given-names:M</infon>
      <infon key="name_6">surname:Rambaldi;given-names:A</infon>
      <infon key="name_7">surname:Garattini;given-names:E</infon>
      <infon key="name_4">surname:Viggiano;given-names:V</infon>
      <infon key="name_5">surname:Barbui;given-names:T</infon>
      <infon key="volume">89</infon>
      <infon key="lpage">1012</infon>
      <infon key="pub-id_pmid">9028332</infon>
      <infon key="source">Blood</infon>
      <infon key="fpage">1001</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>69771</offset>
      <text>Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Bruck;given-names:N</infon>
      <infon key="name_3">surname:Rambaldi;given-names:A</infon>
      <infon key="name_0">surname:Gianni;given-names:M</infon>
      <infon key="name_1">surname:Peviani;given-names:M</infon>
      <infon key="name_6">surname:Kurosaki;given-names:M</infon>
      <infon key="name_7">surname:Paroni;given-names:G</infon>
      <infon key="name_4">surname:Borleri;given-names:G</infon>
      <infon key="name_5">surname:Terao;given-names:M</infon>
      <infon key="volume">26</infon>
      <infon key="name_8">surname:Rochette-Egly;given-names:C</infon>
      <infon key="name_9">surname:Garattini;given-names:E</infon>
      <infon key="lpage">1861</infon>
      <infon key="pub-id_pmid">22354283</infon>
      <infon key="source">Leukemia</infon>
      <infon key="fpage">1850</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>69867</offset>
      <text>p38alphaMAPK interacts with and inhibits RARalpha: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:de Reynies;given-names:A</infon>
      <infon key="name_3">surname:Orsetti;given-names:B</infon>
      <infon key="name_0">surname:Guedj;given-names:M</infon>
      <infon key="name_1">surname:Marisa;given-names:L</infon>
      <infon key="name_6">surname:MacGrogan;given-names:G</infon>
      <infon key="name_7">surname:Lerebours;given-names:F</infon>
      <infon key="name_4">surname:Schiappa;given-names:R</infon>
      <infon key="name_5">surname:Bibeau;given-names:F</infon>
      <infon key="volume">31</infon>
      <infon key="name_8">surname:Finetti;given-names:P</infon>
      <infon key="name_9">surname:Longy;given-names:M</infon>
      <infon key="lpage">1206</infon>
      <infon key="pub-id_pmid">21785460</infon>
      <infon key="source">Oncogene</infon>
      <infon key="fpage">1196</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>70023</offset>
      <text>A refined molecular taxonomy of breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:White;given-names:KP</infon>
      <infon key="volume">137</infon>
      <infon key="name_0">surname:Hua;given-names:S</infon>
      <infon key="name_1">surname:Kittler;given-names:R</infon>
      <infon key="source">Cell</infon>
      <infon key="lpage">1271</infon>
      <infon key="pub-id_pmid">19563758</infon>
      <infon key="fpage">1259</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>70069</offset>
      <text>Genomic antagonism between retinoic acid and estrogen signaling in breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Mundt;given-names:F</infon>
      <infon key="name_3">surname:Forshed;given-names:J</infon>
      <infon key="name_0">surname:Johansson;given-names:HJ</infon>
      <infon key="name_1">surname:Sanchez;given-names:BC</infon>
      <infon key="name_6">surname:Hultin-Rosenberg;given-names:L</infon>
      <infon key="name_7">surname:Lundgren;given-names:B</infon>
      <infon key="name_4">surname:Kovacs;given-names:A</infon>
      <infon key="name_5">surname:Panizza;given-names:E</infon>
      <infon key="name_8">surname:Martens;given-names:U</infon>
      <infon key="name_9">surname:Mathe;given-names:G</infon>
      <infon key="volume">4</infon>
      <infon key="pub-id_pmid">23868472</infon>
      <infon key="source">Nat Commun</infon>
      <infon key="fpage">2175</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>70150</offset>
      <text>Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Mahabeleshwar;given-names:GH</infon>
      <infon key="name_3">surname:Jain;given-names:MK</infon>
      <infon key="name_0">surname:Kannan-Thulasiraman;given-names:P</infon>
      <infon key="name_1">surname:Seachrist;given-names:DD</infon>
      <infon key="name_4">surname:Noy;given-names:N</infon>
      <infon key="source">J Biol Chem</infon>
      <infon key="volume">285</infon>
      <infon key="lpage">19115</infon>
      <infon key="pub-id_pmid">20424164</infon>
      <infon key="fpage">19106</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>70236</offset>
      <text>Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Hibi;given-names:S</infon>
      <infon key="name_3">surname:Yoshimura;given-names:H</infon>
      <infon key="name_0">surname:Kikuchi;given-names:K</infon>
      <infon key="name_1">surname:Tagami;given-names:K</infon>
      <infon key="name_6">surname:Hida;given-names:T</infon>
      <infon key="name_7">surname:Yamauchi;given-names:T</infon>
      <infon key="name_4">surname:Tokuhara;given-names:N</infon>
      <infon key="name_5">surname:Tai;given-names:K</infon>
      <infon key="volume">11</infon>
      <infon key="name_8">surname:Nagai;given-names:M</infon>
      <infon key="lpage">1218</infon>
      <infon key="pub-id_pmid">11354380</infon>
      <infon key="source">Bioorg Med Chem Lett</infon>
      <infon key="fpage">1215</infon>
      <infon key="year">2001</infon>
      <infon key="type">ref</infon>
      <offset>70373</offset>
      <text>Syntheses and evaluation of quinoline derivatives as novel retinoic acid receptor alpha antagonists</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Denardo;given-names:D</infon>
      <infon key="name_3">surname:Li;given-names:Y</infon>
      <infon key="name_0">surname:Kim;given-names:HT</infon>
      <infon key="name_1">surname:Kong;given-names:G</infon>
      <infon key="name_6">surname:Mohsin;given-names:S</infon>
      <infon key="name_7">surname:Hilsenbeck;given-names:SG</infon>
      <infon key="name_4">surname:Uray;given-names:I</infon>
      <infon key="name_5">surname:Pal;given-names:S</infon>
      <infon key="volume">66</infon>
      <infon key="name_8">surname:Bissonnette;given-names:R</infon>
      <infon key="name_9">surname:Lamph;given-names:WW</infon>
      <infon key="lpage">12018</infon>
      <infon key="pub-id_pmid">17178900</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="fpage">12009</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>70473</offset>
      <text>Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Busch;given-names:C</infon>
      <infon key="name_3">surname:Aloysius;given-names:T</infon>
      <infon key="name_0">surname:Knappskog;given-names:S</infon>
      <infon key="name_1">surname:Myklebust;given-names:LM</infon>
      <infon key="name_6">surname:Lillehaug;given-names:JR</infon>
      <infon key="name_7">surname:Pendino;given-names:F</infon>
      <infon key="name_4">surname:Varhaug;given-names:JE</infon>
      <infon key="name_5">surname:Lonning;given-names:PE</infon>
      <infon key="volume">22</infon>
      <infon key="lpage">2215</infon>
      <infon key="pub-id_pmid">21325450</infon>
      <infon key="source">Ann Oncol</infon>
      <infon key="fpage">2208</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>70600</offset>
      <text>RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Wu;given-names:K</infon>
      <infon key="name_3">surname:DeNardo;given-names:D</infon>
      <infon key="name_0">surname:Kong;given-names:G</infon>
      <infon key="name_1">surname:Kim;given-names:HT</infon>
      <infon key="name_6">surname:Lamph;given-names:WW</infon>
      <infon key="name_7">surname:Bissonnette;given-names:R</infon>
      <infon key="name_4">surname:Hilsenbeck;given-names:SG</infon>
      <infon key="name_5">surname:Xu;given-names:XC</infon>
      <infon key="volume">65</infon>
      <infon key="name_8">surname:Dannenberg;given-names:AJ</infon>
      <infon key="name_9">surname:Brown;given-names:PH</infon>
      <infon key="lpage">3469</infon>
      <infon key="pub-id_pmid">15833882</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="fpage">3462</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>70703</offset>
      <text>The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Sonnenberg;given-names:M</infon>
      <infon key="name_3">surname:McClellan;given-names:M</infon>
      <infon key="name_0">surname:van der Kuip;given-names:H</infon>
      <infon key="name_1">surname:Murdter;given-names:TE</infon>
      <infon key="name_6">surname:Simon;given-names:W</infon>
      <infon key="name_7">surname:Fritz;given-names:P</infon>
      <infon key="name_4">surname:Gutzeit;given-names:S</infon>
      <infon key="name_5">surname:Gerteis;given-names:A</infon>
      <infon key="name_8">surname:Aulitzky;given-names:WE</infon>
      <infon key="volume">6</infon>
      <infon key="pub-id_pmid">16603054</infon>
      <infon key="source">BMC Cancer</infon>
      <infon key="fpage">86</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>70910</offset>
      <text>Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Cawley;given-names:NX</infon>
      <infon key="name_3">surname:Dhanvantari;given-names:S</infon>
      <infon key="name_0">surname:Lee;given-names:TK</infon>
      <infon key="name_1">surname:Murthy;given-names:SR</infon>
      <infon key="name_6">surname:Lau;given-names:T</infon>
      <infon key="name_7">surname:Ma;given-names:S</infon>
      <infon key="name_4">surname:Hewitt;given-names:SM</infon>
      <infon key="name_5">surname:Lou;given-names:H</infon>
      <infon key="volume">121</infon>
      <infon key="name_8">surname:Huynh;given-names:T</infon>
      <infon key="name_9">surname:Wesley;given-names:RA</infon>
      <infon key="lpage">892</infon>
      <infon key="pub-id_pmid">21285511</infon>
      <infon key="source">J Clin Invest</infon>
      <infon key="fpage">880</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>71036</offset>
      <text>An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Vignetti;given-names:M</infon>
      <infon key="name_3">surname:Thiede;given-names:C</infon>
      <infon key="name_0">surname:Lo-Coco;given-names:F</infon>
      <infon key="name_1">surname:Avvisati;given-names:G</infon>
      <infon key="name_6">surname:Ferrara;given-names:F</infon>
      <infon key="name_7">surname:Fazi;given-names:P</infon>
      <infon key="name_4">surname:Orlando;given-names:SM</infon>
      <infon key="name_5">surname:Iacobelli;given-names:S</infon>
      <infon key="volume">369</infon>
      <infon key="name_8">surname:Cicconi;given-names:L</infon>
      <infon key="name_9">surname:Di Bona;given-names:E</infon>
      <infon key="lpage">121</infon>
      <infon key="pub-id_pmid">23841729</infon>
      <infon key="source">N Engl J Med</infon>
      <infon key="fpage">111</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>71184</offset>
      <text>Retinoic acid and arsenic trioxide for acute promyelocytic leukemia</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Li;given-names:L</infon>
      <infon key="volume">29</infon>
      <infon key="name_0">surname:Maitra;given-names:U</infon>
      <infon key="name_1">surname:Parks;given-names:JS</infon>
      <infon key="source">Mol Cell Biol</infon>
      <infon key="lpage">5997</infon>
      <infon key="pub-id_pmid">19752193</infon>
      <infon key="fpage">5989</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>71252</offset>
      <text>An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Chambon;given-names:P</infon>
      <infon key="name_0">surname:Mark;given-names:M</infon>
      <infon key="name_1">surname:Ghyselinck;given-names:NB</infon>
      <infon key="source">Nucl Recept Signal</infon>
      <infon key="volume">7</infon>
      <infon key="pub-id_pmid">19381305</infon>
      <infon key="fpage">e002</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>71410</offset>
      <text>Function of retinoic acid receptors during embryonic development</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Ocana;given-names:A</infon>
      <infon key="name_3">surname:Pandiella;given-names:A</infon>
      <infon key="name_0">surname:Montero;given-names:JC</infon>
      <infon key="name_1">surname:Seoane;given-names:S</infon>
      <infon key="source">Oncogene</infon>
      <infon key="volume">30</infon>
      <infon key="lpage">1071</infon>
      <infon key="pub-id_pmid">21042280</infon>
      <infon key="fpage">1059</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>71475</offset>
      <text>P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Pandiella;given-names:A</infon>
      <infon key="volume">25</infon>
      <infon key="name_0">surname:Montero;given-names:JC</infon>
      <infon key="name_1">surname:Seoane;given-names:S</infon>
      <infon key="source">Cell Signal</infon>
      <infon key="lpage">2289</infon>
      <infon key="pub-id_pmid">23899556</infon>
      <infon key="fpage">2281</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>71602</offset>
      <text>Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Urosevic;given-names:J</infon>
      <infon key="name_3">surname:Guiu;given-names:M</infon>
      <infon key="name_0">surname:Morales;given-names:M</infon>
      <infon key="name_1">surname:Arenas;given-names:EJ</infon>
      <infon key="name_6">surname:Fenwick;given-names:RB</infon>
      <infon key="name_7">surname:Fernandez-Ruiz;given-names:S</infon>
      <infon key="name_4">surname:Fernandez;given-names:E</infon>
      <infon key="name_5">surname:Planet;given-names:E</infon>
      <infon key="volume">6</infon>
      <infon key="name_8">surname:Salvatella;given-names:X</infon>
      <infon key="name_9">surname:Reverter;given-names:D</infon>
      <infon key="lpage">881</infon>
      <infon key="pub-id_pmid">24867881</infon>
      <infon key="source">EMBO Mol Med</infon>
      <infon key="fpage">865</infon>
      <infon key="year">2014</infon>
      <infon key="type">ref</infon>
      <offset>71699</offset>
      <text>RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation</text>
    </passage>
    <passage>
      <infon key="volume">30</infon>
      <infon key="name_0">surname:Noy;given-names:N</infon>
      <infon key="source">Annu Rev Nutr</infon>
      <infon key="lpage">217</infon>
      <infon key="pub-id_pmid">20415582</infon>
      <infon key="fpage">201</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>71791</offset>
      <text>Between death and survival: retinoic acid in regulation of apoptosis</text>
    </passage>
    <passage>
      <infon key="volume">22</infon>
      <infon key="name_0">surname:Nwankwo;given-names:JO</infon>
      <infon key="source">Anticancer Res</infon>
      <infon key="lpage">4135</infon>
      <infon key="pub-id_pmid">12553043</infon>
      <infon key="fpage">4129</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>71860</offset>
      <text>Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)-catechin in Dunning rat invasive prostate adenocarcinoma cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Cheang;given-names:MC</infon>
      <infon key="name_3">surname:Leung;given-names:S</infon>
      <infon key="name_0">surname:Parker;given-names:JS</infon>
      <infon key="name_1">surname:Mullins;given-names:M</infon>
      <infon key="name_6">surname:Davies;given-names:S</infon>
      <infon key="name_7">surname:Fauron;given-names:C</infon>
      <infon key="name_4">surname:Voduc;given-names:D</infon>
      <infon key="name_5">surname:Vickery;given-names:T</infon>
      <infon key="volume">27</infon>
      <infon key="name_8">surname:He;given-names:X</infon>
      <infon key="name_9">surname:Hu;given-names:Z</infon>
      <infon key="lpage">1167</infon>
      <infon key="pub-id_pmid">19204204</infon>
      <infon key="source">J Clin Oncol</infon>
      <infon key="fpage">1160</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>72004</offset>
      <text>Supervised risk predictor of breast cancer based on intrinsic subtypes</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Gardini;given-names:G</infon>
      <infon key="name_3">surname:Bassano;given-names:C</infon>
      <infon key="name_0">surname:Paroni;given-names:G</infon>
      <infon key="name_1">surname:Fratelli;given-names:M</infon>
      <infon key="name_6">surname:Guarnaccia;given-names:V</infon>
      <infon key="name_7">surname:Ubezio;given-names:P</infon>
      <infon key="name_4">surname:Flora;given-names:M</infon>
      <infon key="name_5">surname:Zanetti;given-names:A</infon>
      <infon key="volume">31</infon>
      <infon key="name_8">surname:Centritto;given-names:F</infon>
      <infon key="name_9">surname:Terao;given-names:M</infon>
      <infon key="lpage">3443</infon>
      <infon key="pub-id_pmid">22056878</infon>
      <infon key="source">Oncogene</infon>
      <infon key="fpage">3431</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>72075</offset>
      <text>Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer&#160;with coamplification of ERBB2 and RARA</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Shaw;given-names:NS</infon>
      <infon key="name_3">surname:Travis;given-names:SN</infon>
      <infon key="name_0">surname:Schug;given-names:TT</infon>
      <infon key="name_1">surname:Berry;given-names:DC</infon>
      <infon key="name_4">surname:Noy;given-names:N</infon>
      <infon key="source">Cell</infon>
      <infon key="volume">129</infon>
      <infon key="lpage">733</infon>
      <infon key="pub-id_pmid">17512406</infon>
      <infon key="fpage">723</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>72209</offset>
      <text>Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Noy;given-names:N</infon>
      <infon key="volume">278</infon>
      <infon key="name_0">surname:Shaw;given-names:N</infon>
      <infon key="name_1">surname:Elholm;given-names:M</infon>
      <infon key="source">J Biol Chem</infon>
      <infon key="lpage">41592</infon>
      <infon key="pub-id_pmid">12963727</infon>
      <infon key="fpage">41589</infon>
      <infon key="year">2003</infon>
      <infon key="type">ref</infon>
      <offset>72326</offset>
      <text>Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Scudiero;given-names:D</infon>
      <infon key="name_3">surname:Monks;given-names:A</infon>
      <infon key="name_0">surname:Skehan;given-names:P</infon>
      <infon key="name_1">surname:Storeng;given-names:R</infon>
      <infon key="name_6">surname:Warren;given-names:JT</infon>
      <infon key="name_7">surname:Bokesch;given-names:H</infon>
      <infon key="name_4">surname:McMahon;given-names:J</infon>
      <infon key="name_5">surname:Vistica;given-names:D</infon>
      <infon key="volume">82</infon>
      <infon key="name_8">surname:Kenney;given-names:S</infon>
      <infon key="name_9">surname:Boyd;given-names:MR</infon>
      <infon key="lpage">1112</infon>
      <infon key="pub-id_pmid">2359136</infon>
      <infon key="source">J Natl Cancer Inst</infon>
      <infon key="fpage">1107</infon>
      <infon key="year">1990</infon>
      <infon key="type">ref</infon>
      <offset>72438</offset>
      <text>New colorimetric cytotoxicity assay for anticancer-drug screening</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Rossetti;given-names:S</infon>
      <infon key="name_3">surname:Ren;given-names:M</infon>
      <infon key="name_0">surname:Somenzi;given-names:G</infon>
      <infon key="name_1">surname:Sala;given-names:G</infon>
      <infon key="name_4">surname:Ghidoni;given-names:R</infon>
      <infon key="name_5">surname:Sacchi;given-names:N</infon>
      <infon key="volume">2</infon>
      <infon key="pub-id_pmid">17786207</infon>
      <infon key="source">PLoS ONE</infon>
      <infon key="fpage">e836</infon>
      <infon key="year">2007</infon>
      <infon key="type">ref</infon>
      <offset>72504</offset>
      <text>Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Parker;given-names:J</infon>
      <infon key="name_3">surname:Hastie;given-names:T</infon>
      <infon key="name_0">surname:Sorlie;given-names:T</infon>
      <infon key="name_1">surname:Tibshirani;given-names:R</infon>
      <infon key="name_6">surname:Deng;given-names:S</infon>
      <infon key="name_7">surname:Johnsen;given-names:H</infon>
      <infon key="name_4">surname:Marron;given-names:JS</infon>
      <infon key="name_5">surname:Nobel;given-names:A</infon>
      <infon key="volume">100</infon>
      <infon key="name_8">surname:Pesich;given-names:R</infon>
      <infon key="name_9">surname:Geisler;given-names:S</infon>
      <infon key="lpage">8423</infon>
      <infon key="pub-id_pmid">12829800</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="fpage">8418</infon>
      <infon key="year">2003</infon>
      <infon key="type">ref</infon>
      <offset>72597</offset>
      <text>Repeated observation of breast tumor subtypes in independent gene expression data sets</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Bernardon;given-names:JM</infon>
      <infon key="name_3">surname:Michel;given-names:S</infon>
      <infon key="name_0">surname:Szondy;given-names:Z</infon>
      <infon key="name_1">surname:Reichert;given-names:U</infon>
      <infon key="name_6">surname:Ajzner;given-names:E</infon>
      <infon key="name_7">surname:Fesus;given-names:L</infon>
      <infon key="name_4">surname:Toth;given-names:R</infon>
      <infon key="name_5">surname:Ancian;given-names:P</infon>
      <infon key="volume">51</infon>
      <infon key="lpage">982</infon>
      <infon key="pub-id_pmid">9187263</infon>
      <infon key="source">Mol Pharmacol</infon>
      <infon key="fpage">972</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>72684</offset>
      <text>Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Schiffer;given-names:CA</infon>
      <infon key="name_3">surname:Appelbaum;given-names:FR</infon>
      <infon key="name_0">surname:Tallman;given-names:MS</infon>
      <infon key="name_1">surname:Andersen;given-names:JW</infon>
      <infon key="name_6">surname:Shepherd;given-names:L</infon>
      <infon key="name_7">surname:Willman;given-names:C</infon>
      <infon key="name_4">surname:Feusner;given-names:JH</infon>
      <infon key="name_5">surname:Ogden;given-names:A</infon>
      <infon key="volume">337</infon>
      <infon key="name_8">surname:Bloomfield;given-names:CD</infon>
      <infon key="name_9">surname:Rowe;given-names:JM</infon>
      <infon key="lpage">1028</infon>
      <infon key="pub-id_pmid">9321529</infon>
      <infon key="source">N Engl J Med</infon>
      <infon key="fpage">1021</infon>
      <infon key="year">1997</infon>
      <infon key="type">ref</infon>
      <offset>72827</offset>
      <text>All-trans-retinoic acid in acute promyelocytic leukemia</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Kurosaki;given-names:M</infon>
      <infon key="name_3">surname:Zanetti;given-names:A</infon>
      <infon key="name_0">surname:Terao;given-names:M</infon>
      <infon key="name_1">surname:Fratelli;given-names:M</infon>
      <infon key="name_6">surname:Tsykin;given-names:A</infon>
      <infon key="name_7">surname:Lupi;given-names:M</infon>
      <infon key="name_4">surname:Guarnaccia;given-names:V</infon>
      <infon key="name_5">surname:Paroni;given-names:G</infon>
      <infon key="volume">286</infon>
      <infon key="name_8">surname:Gianni;given-names:M</infon>
      <infon key="name_9">surname:Goodall;given-names:GJ</infon>
      <infon key="lpage">4042</infon>
      <infon key="pub-id_pmid">21131358</infon>
      <infon key="source">J Biol Chem</infon>
      <infon key="fpage">4027</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>72883</offset>
      <text>Induction of miR-21 by retinoic acid in estrogen-receptor-positive breast carcinoma cells: biological correlates and molecular targets</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Isoherranen;given-names:N</infon>
      <infon key="volume">80</infon>
      <infon key="name_0">surname:Thatcher;given-names:JE</infon>
      <infon key="name_1">surname:Zelter;given-names:A</infon>
      <infon key="source">Biochem Pharmacol</infon>
      <infon key="lpage">912</infon>
      <infon key="pub-id_pmid">20513361</infon>
      <infon key="fpage">903</infon>
      <infon key="year">2010</infon>
      <infon key="type">ref</infon>
      <offset>73018</offset>
      <text>The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Narasimhan;given-names:B</infon>
      <infon key="name_3">surname:Chu;given-names:G</infon>
      <infon key="name_0">surname:Tibshirani;given-names:R</infon>
      <infon key="name_1">surname:Hastie;given-names:T</infon>
      <infon key="source">Proc Natl Acad Sci USA</infon>
      <infon key="volume">99</infon>
      <infon key="lpage">6572</infon>
      <infon key="pub-id_pmid">12011421</infon>
      <infon key="fpage">6567</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>73101</offset>
      <text>Diagnosis of multiple cancer types by shrunken centroids of gene expression</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Zelter;given-names:A</infon>
      <infon key="name_3">surname:Lutz;given-names:JD</infon>
      <infon key="name_0">surname:Topletz;given-names:AR</infon>
      <infon key="name_1">surname:Thatcher;given-names:JE</infon>
      <infon key="name_6">surname:Isoherranen;given-names:N</infon>
      <infon key="name_4">surname:Tay;given-names:S</infon>
      <infon key="name_5">surname:Nelson;given-names:WL</infon>
      <infon key="volume">83</infon>
      <infon key="lpage">163</infon>
      <infon key="pub-id_pmid">22020119</infon>
      <infon key="source">Biochem Pharmacol</infon>
      <infon key="fpage">149</infon>
      <infon key="year">2012</infon>
      <infon key="type">ref</infon>
      <offset>73177</offset>
      <text>Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Foti;given-names:RS</infon>
      <infon key="name_3">surname:Shimshoni;given-names:JA</infon>
      <infon key="name_0">surname:Topletz;given-names:AR</infon>
      <infon key="name_1">surname:Tripathy;given-names:S</infon>
      <infon key="name_4">surname:Nelson;given-names:WL</infon>
      <infon key="name_5">surname:Isoherranen;given-names:N</infon>
      <infon key="volume">87</infon>
      <infon key="lpage">441</infon>
      <infon key="pub-id_pmid">25492813</infon>
      <infon key="source">Mol Pharmacol</infon>
      <infon key="fpage">430</infon>
      <infon key="year">2015</infon>
      <infon key="type">ref</infon>
      <offset>73278</offset>
      <text>Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids</text>
    </passage>
    <passage>
      <infon key="volume">188</infon>
      <infon key="name_0">surname:Uray;given-names:IP</infon>
      <infon key="name_1">surname:Brown;given-names:PH</infon>
      <infon key="source">Recent Results Cancer Res</infon>
      <infon key="lpage">162</infon>
      <infon key="pub-id_pmid">21253797</infon>
      <infon key="fpage">147</infon>
      <infon key="year">2011</infon>
      <infon key="type">ref</infon>
      <offset>73416</offset>
      <text>Chemoprevention of hormone receptor-negative breast cancer: new approaches needed</text>
    </passage>
    <passage>
      <infon key="volume">1</infon>
      <infon key="name_0">surname:Vichai;given-names:V</infon>
      <infon key="name_1">surname:Kirtikara;given-names:K</infon>
      <infon key="source">Nat Protoc</infon>
      <infon key="lpage">1116</infon>
      <infon key="pub-id_pmid">17406391</infon>
      <infon key="fpage">1112</infon>
      <infon key="year">2006</infon>
      <infon key="type">ref</infon>
      <offset>73498</offset>
      <text>Sulforhodamine B colorimetric assay for cytotoxicity screening</text>
    </passage>
    <passage>
      <infon key="volume">110</infon>
      <infon key="name_0">surname:Voigt;given-names:W</infon>
      <infon key="source">Methods Mol Med</infon>
      <infon key="lpage">48</infon>
      <infon key="pub-id_pmid">15901925</infon>
      <infon key="fpage">39</infon>
      <infon key="year">2005</infon>
      <infon key="type">ref</infon>
      <offset>73561</offset>
      <text>Sulforhodamine B assay and chemosensitivity</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Darby;given-names:S</infon>
      <infon key="name_3">surname:Saif;given-names:R</infon>
      <infon key="name_0">surname:Wright;given-names:PK</infon>
      <infon key="name_1">surname:May;given-names:FE</infon>
      <infon key="name_4">surname:Lennard;given-names:TW</infon>
      <infon key="name_5">surname:Westley;given-names:BR</infon>
      <infon key="volume">2</infon>
      <infon key="lpage">475</infon>
      <infon key="pub-id_pmid">19294005</infon>
      <infon key="source">Int J Clin Exp Pathol</infon>
      <infon key="fpage">463</infon>
      <infon key="year">2009</infon>
      <infon key="type">ref</infon>
      <offset>73605</offset>
      <text>Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Xu;given-names:XC</infon>
      <infon key="name_3">surname:Hill;given-names:J</infon>
      <infon key="name_0">surname:Wu;given-names:K</infon>
      <infon key="name_1">surname:Zhang;given-names:Y</infon>
      <infon key="name_6">surname:Mohsin;given-names:SK</infon>
      <infon key="name_7">surname:Hilsenbeck;given-names:SG</infon>
      <infon key="name_4">surname:Celestino;given-names:J</infon>
      <infon key="name_5">surname:Kim;given-names:HT</infon>
      <infon key="volume">62</infon>
      <infon key="name_8">surname:Lamph;given-names:WW</infon>
      <infon key="name_9">surname:Bissonette;given-names:R</infon>
      <infon key="lpage">6380</infon>
      <infon key="pub-id_pmid">12438218</infon>
      <infon key="source">Cancer Res</infon>
      <infon key="fpage">6376</infon>
      <infon key="year">2002</infon>
      <infon key="type">ref</infon>
      <offset>73707</offset>
      <text>The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen-receptor-negative mammary tumors in transgenic mice</text>
    </passage>
    <passage>
      <infon key="name_2">surname:Zong;given-names:Q</infon>
      <infon key="name_3">surname:Fang;given-names:DD</infon>
      <infon key="name_0">surname:Zhang;given-names:CC</infon>
      <infon key="name_1">surname:Yan;given-names:Z</infon>
      <infon key="name_6">surname:Chen;given-names:E</infon>
      <infon key="name_7">surname:Lira;given-names:ME</infon>
      <infon key="name_4">surname:Painter;given-names:C</infon>
      <infon key="name_5">surname:Zhang;given-names:Q</infon>
      <infon key="volume">2</infon>
      <infon key="name_8">surname:John-Baptiste;given-names:A</infon>
      <infon key="name_9">surname:Christensen;given-names:JG</infon>
      <infon key="lpage">242</infon>
      <infon key="pub-id_pmid">23408105</infon>
      <infon key="source">Stem Cells Transl Med</infon>
      <infon key="fpage">233</infon>
      <infon key="year">2013</infon>
      <infon key="type">ref</infon>
      <offset>73849</offset>
      <text>Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models</text>
    </passage>
    <passage>
      <infon key="type">title_1</infon>
      <offset>73951</offset>
      <text>Supporting Information</text>
    </passage>
  </document>
</collection>
